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ABSTRACT
PACAP: A NOVEL NEUROPEPTIDE FOR PITUITARY GONADOTROPH
MATURATION, FUNCTION AND REGULATION
Rongqiang Yang
May 2, 2013
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 38-amino
acid C-terminally -amidated peptide that was first isolated from ovine
hypothalamic extracts on the basis of its ability to stimulate cAMP production in
anterior pituitary cells. As a member of the vasoactive intestinal polypeptide
(VIP)/secretin/growth hormone-releasing hormone/glucagon superfamily, PACAP
has been well conserved during evolution from sea squirt to humans, which
suggests important biological functions. Two types of PACAP receptors have
been characterized. PAC1-R is the only one PACAP-specific receptor with high
affinity.
Although PACAP was first found in hypothalamus, it is also expressed in
the pituitary. In the research to be presented, PACAP and PAC1-R mRNA
expression in the rodent pituitary and in gonadotroph cell lines were explored
using semi-quantitative PCR, laser capture micro-dissection (LCM) and single
cell PCR. The level of pituitary PACAP expression is high in the fetus and
declines after birth. Most of pituitary PACAP is from gonadotrophs. PAC1-R in
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fetal pituitary exists as the Hop and short forms, and the level of the short form
decreases after birth.
The effects of PACAP on gonadotropins synthesis and secretion were
studied in vivo and in vitro. The action of PACAP on LH and FSH was
investigated utilizing micro-pump implanted, containing PACAP38 or the
antagonist, PACAP 6-38, in pre-pubertal male rats. Protein and mRNA analysis
revealed that PACAP suppresses FSH presumably through increased follistatin,
but had no significant influence on LH. The existence of PACAP, therefore, likely
contributes to maintain an appropriate gonadotropin environment during sexual
development.
We also studied pituitary cell cultures and gonadotroph cell lines to
understand why PACAP expression in pituitary is high in the fetus, and declines
at birth. PACAP was found to stimulate its own expression in that the PACAP 638 antagonist reduced the PACAP mRNA level in primary cell cultures, and
PACAP38 induced high activity of PACAP promoter in gonadotroph cell lines.
Furthermore, we found preliminary evidence to support the ideal that dopamine
receptor 2 (Drd2) signaling may explain the neonatal decrease in pituitary
PACAP mRNA levels. Finally, we propose that the decrease in PACAP results in
a fall in pituitary follistatin, allowing for increased activin signaling which
increases FSH

facilitates the sexual maturation of the gonads.
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CHAPTER ONE

GENERAL INTRODUCTION

1.

General introduction of PACAP

1.1. Discovery of Pituitary Adenylate Cyclase-Activating Polypeptide
(PACAP)
Each of the classical hypothalamic hypophysiotrophic hormones had been
isolated and identified by the mid-1980s. Since then, each of the classical
releasing hormones, TRH, LHRH, GHRH, and CRH had been demonstrated to
stimulate adenylate cyclase in cultured pituitary cells (Culler et al., 1984; Labrie
et al., 1979; Labrie et al., 1982). Arimura and colleagues proposed to find out
whether there were undiscovered hypothalamic releasing hormones which would
also stimulate adenylate cyclase. This strategy led to the identification of a
peptide in ovine hypothalamus that they named Pituitary Adenylate CyclaseActivating Polypeptide (PACAP) (Miyata et al., 1989).
Through sequence analysis, PACAP was shown to have 38-amino-acids
(Miyata et al., 1989), but was also present in smaller amounts as a shorter
amidated form containing only the N-terminal 27 amino acids (Miyata et al.,
1990). The two forms with 38 and 27 residues were then named PACAP38 and
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PACAP27. PACAP38 and PACAP27 are equivalent stimulators of adenylate
cyclase (Miyata et al., 1990). However, PACAP38 and PACAP27 bind with
different affinities to some PACAP receptor variants (Dautzenberg et al., 1999;
Pantaloni et al., 1996).
1.2. Structure of Pituitary Adenylate Cyclase Activating Polypeptide
As a small peptide, the secondary structure of PACAP is relatively simple.
Circular dichroism and nuclear magnetic resonance indicated that PACAP27 was
characterized by a helical conformation of various lengths in different mediums
(Inooka et al., 1992). PACAP38 has similar conformation to PACAP27 within the
1-to-27 region and is connected with a short helix (28-to-38 region) by a flexible
hinge (Wray et al., 1993). The conformation of PACAP may change following
binding with PACAP receptors (Inooka et al., 2001; Sun et al., 2007).
1.3. The Gene Encoding PACAP
The PACAP genes from different species were cloned soon after its
discovery in 1989 (Inooka et al., 1992; Kimura et al., 1990; Ogi et al., 1990). The
PACAP gene has five exons and four introns, and the introns are bounded by the
consensus splicing sequences 5’-GT and 3’-AG. PACAP38 and PACAP27 are
encoded by exon 5 whereas Exon 4 encodes PRP (PACAP-related peptide) and
exon 1 is un-translated (Hannibal et al., 1995; Hosoya et al., 1992). In the
PACAP gene, two CRE (cAMP-response-like element) and growth hormone
transactivator factor-1 response elements, a GATA box, and a C-rich domain
with GC boxes are conserved through different species (Ohkubo et al., 1992;
White et al., 2000). The organization of the PACAP gene is similar to the that of
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the VIP and GHRH genes, which are in the same superfamily (Lamperti et al.,
1991; Mayo et al., 1985; Ohkubo et al., 1992).
1.4. Processing of the PACAP Precursor
The PACAP precursors contain seven mono- or dibasic residues, which
are similar to VIP precursors. They can be cleaved by various prohormone
convertases (PC) including PC1, PC2, PC4, PC5, PC7, Furin, and paired basic
amino acid-cleaving enzyme 4 (PACE4) (Seidah and Chretien, 1999; Seidah et
al., 1994; Seidah et al., 1998). In mammals, the processing of the PACAP
precursors has been thoroughly characterized. The first, cleavage occurs at three
dibasic sites, Arg79-Arg80, Lys129-Arg130, and Arg170-Arg171, to generate a large
intermediate precursor of PRP (big PRP) and a glycine-extended form of
PACAP38. Next, the big PRP is cleaved at a single Arg110 followed by hydrolysis
of this C-terminal Arg residue by carboxypeptidase E, H or M to generate PRP
(Eipper et al., 1992; Rouille et al., 1995). For PACAP38, the Gly169 residue
allows peptidyl glycine -amidating monooxygenase to amidate the Lys168
residue at the C-terminal extremity. In the final step, amidated PACAP27 is
generated through the cleavage of tripeptide Gly158-Lys159-Arg160 (Okazaki et al.,
1992). In sum, the processing of PACAP precursor yields three products,
PACAP38, PACAP27 and PRPs.
PACAP has limited metabolic stability in the blood circulation with a halflife between 2 and 10 min after injection into mice or humans (Li et al., 2007; Zhu
et al., 2003). The proteolytic enzymes dipeptidyl peptidase IV and prolyl
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oligopeptidase have been reported to be involved in the degradation of PACAP
(Ahren and Hughes, 2005; Tenorio-Laranga et al., 2009).
1.5. Phylogenetic Evolution of PACAP

Figure 1. Amino acid sequences of PACAP from different species. Percentages
indicate amino acids identical between non-mammalian PACAP38 and
mammalian PACAP38.

PACAP is a member of the secretin/glucagon/vasoactive intestinal
polypeptide (VIP) superfamily, which includes glucagon, glucagon-like peptide-1
(GLP1), glucagon-like peptide-2 (GLP-2), glucose-dependent insulinotropic
polypeptide (GIP), growth hormone-releasing hormone (GHRH), peptide histidine
isoleucine (PHI) or peptide histidine methionine (PHM), PACAP, and VIP.
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Compared to the other superfamily peptide hormones, PACAP is unique for its
well-conserved primary amino acid sequence in vertebrates (Chartrel et al.,
1991). The N-terminal 1 to 27 region of PACAP is responsible for the biological
activity of the peptide. This region has been fully conserved in most vertebrate
species, except for a few species with a single amino acid substitution (Fig. 1)
(Lee et al., 2009; McRory et al., 1997; Xu and Volkoff, 2009). On the other hand,
the C-terminal portion of PACAP38 is more variable and is not crucial for PACAP
biological functions (Fig. 1).
1.6. PACAP Receptors
VIP and PACAP are the most closely related of these peptides because
the sequence of PACAP38 shows 68% identity with VIP (Ohkubo et al., 1992).
Consequently, PACAP and VIP signaling can be mediated through similar
receptors. Soon after the discovery of PACAP, two classes of PACAP binding
sites were characterized on the basis of their relative affinities for PACAP27 and
VIP (Gottschall et al., 1990; Lam et al., 1990). Type I binding sites exhibit high
affinity for PACAP and much lower affinity for VIP (Cauvin et al., 1990; Suda et
al., 1992). Type II binding sites possess similar affinity for PACAP and VIP
(Gottschall et al., 1990; Lam et al., 1990). From the two types of binding sites,
there are three PACAP receptors cloned, which were termed PAC1, VPAC1 and
VPAC2 receptors by the International Union of Pharmacology (Seidah et al.,
1998). The PAC1 receptor, with 495-amino acid residues, is the type I receptor,
which shows much higher affinity (100 to 1000-fold) for PACAP than VIP
(Pisegna and Wank, 1993). The VPAC1 and VPAC2 receptors are type II
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receptors, which have similar affinity for PACAP and VIP (Ishihara et al., 1992;
Lutz et al., 1993). VPAC1, 2 and PAC1-R all belong to class B of G proteincoupled receptors families (GPCRs), which mediate many important biological
functions (Hoare, 2005). There are three main mammalian GPCR families (A, B
and C). The group B or secretin receptor family consists primarily of peptide
hormone and neuropeptide receptors such as the secretin, calcitonin, VIP and
PACAP receptors. As members of the same family, VPAC1, VPAC2 and PAC1
receptors share some common molecular properties, such as a large N-terminal
extracellular domain (>120 residues), an N-terminal hydrophobic domain, and six
conserved cysteine residents in the N-terminal extracellular domain and multiple
consensus N-glycosylation sites (Gaudin et al., 1999; Laburthe et al., 1996).
The N-terminal extracellular domain of the PAC1 receptor is a major
binding site for the central and C-terminal helical segments of PACAP (Bourgault
et al., 2008; Cao et al., 1995). PAC1-R is specific for binding with PACAP but not
VIP because of different sequence regions (4 -13 and 24 - 28) between
PACAP27 and VIP are PAC1-R selective sites (Onoue et al., 2001; Schafer et al.,
1999).
PAC1-R has nine subtypes resulting from alternative splicing after
transcription (Fig. 2). Six of these subtypes are distinguished from each other by
the absence or presence of two cassettes named Hip and Hop, which are located
at the end of the 3rd intracellular loop of PAC1-R (Spengler et al., 1993). They are
named PAC1-R-Short, PAC1-R-Hop1, PAC1-R-Hop2, PAC1-R-Hip, and PAC1R-Hiphop1 and PAC1-R-Hiphop2. Beyond these six variants, more subtypes
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were recently discovered including PAC1-R-Vs, PAC1-R-TM4 and PAC1-R-3a
(Chatterjee et al., 1996; Daniel et al., 2001; Pantaloni et al., 1996). PAC1-R
variants have different affinity for PACAP. Furthermore, the variants may mediate
different signaling pathways in various cell types (Alexandre et al., 2002; Dickson
and Finlayson, 2009; McCulloch et al., 2001; Niewiadomski et al., 2002).

Figure 2. Schematic illustrations of the structure of the PAC1-Rs. Nine variants of
the PAC1-R have been identified.

1.7. Distribution of PACAP and its Receptors
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Soon after the discovery of PACAP, distribution of the polypeptide was
investigated by immunoassay and PCR (Arimura et al., 1991). PACAP is widely
distributed but is found in highest concentration in the Central Nervous System
(CNS). PACAP is found in various brain regions, including the hypothalamic area,
cerebral cortex, amygdala, hippocampus, pineal gland, substantial nigra,
cerebellum, and pons, and is found in both cell bodies and fibers (Dickson and
Finlayson, 2009). Although PACAP and VIP are closely related in the same
superfamily, their distributions in the CNS are different (Masuo et al., 1993). For
instance, in the thalamus, VIP positive fibers and PACAP fibers are localized in
different regions. While VIP fibers run up the walls of the third ventricle, PACAP
fibers are observed in the central thalamic nuclei (Koves et al., 1991). Similar
situations occur in other brain regions, such as stria terminalis, brainstem and
posterior pituitary (Koves et al., 1994; Vereczki et al., 2003). PACAP38 has been
demonstrated as the major molecular form in the CNS (Arimura et al., 1991;
Hannibal et al., 1995; Masuo et al., 1993; Piggins et al., 1996).
PACAP is also found in many peripheral tissues, such as most endocrine
glands, the gastrointestinal tract, gonads, muscles and peripheral nervous
system (Vaudry et al., 2009). PACAP38 is the predominant form in these tissues
as in the CNS. In the rat testis, the concentration of PACAP is higher than any
other tissues, and PACAP mRNA is only present in germ cells (Arimura et al.,
1991; Hannibal and Fahrenkrug, 1995; Shioda et al., 1994). The ovary also
contains PACAP but at a much lower concentration compared to testis
(Steenstrup et al., 1995). PACAP is found in nerve fibers that connect with the
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musculature of the gastrointestinal tracts and circulatory system (Cardell et al.,
1991; Hauser-Kronberger et al., 1996; Olsson and Holmgren, 1994). In the
immune system, PACAP is present in the lymphoid tissues, including the thymus,
spleen and in the peritoneal macrophages (Vaudry et al., 2009). Unlike in the
CNS, PACAP and VIP in peripheral tissues are often found in the same cells,
and show similar expression patterns. PACAP and VIP have been co-localized in
cell bodies and nerve fibers in esophageal sphincter, gut, parathyroid glands and
the respiratory tract in mammals (Luts and Sundler, 1994; Sundler et al., 1992;
Uddman et al., 1991). PACAP is found in the anterior pituitary and in high
concentration during fetal life (Moore et al., 2009a).
VPAC and PAC1-R are widely expressed in many kinds of tissues (Vaudry
et al., 2009). In the Nervous system, high concentrations of PAC1-R are found in
many brain structures including olfactory bulb, cerebral cortex, septum, amygdala,
cerebellum, hippocampus, thalamus, pons and hypothalamus (Vaudry et al.,
2009). VPAC receptor expression levels are much lower than PAC1-R in many
brain regions such as cerebellum and hypothalamic nuclei. Furthermore, the two
VPAC receptors, VPAC1-R and VPAC2-R, have completely different distributions
in the rat CNS (Ishihara et al., 1992; Usdin et al., 1994). Hippocampus is the only
region of the CNS in which both VPAC1-R and VPAC2-R are found in (Usdin et
al., 1994). In summary, the expression and density of PAC1-R is more abundant
and wider compared to VPAC receptors in the CNS.
Outside the CNS, the PAC1-R has been characterized in most endocrine
tissues, including the pituitary, pancreas, placenta, adrenal, ovary and testis
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(Vaudry et al., 2009). In the testis, PAC1-R is found in germ cells, Leydig cells
and Sertoli cells (Daniel et al., 2001; Romanelli et al., 1997; Shivers et al., 1991).
In the immune system, PAC1-R is expressed in rat peritoneal macrophages but
not in peritoneal lymphocytes (Delgado et al., 1996; Ganea, 1996). VPAC
receptors exhibit a distinct distribution patterns in peripheral organs as well. The
VPAC1-R is highly expressed in lung, intestine, pancreas and adrenal medulla.
However, VPAC2-R is present within the pituitary, testis and ovary, spleen, and
adrenal cortex (Vaudry et al., 2009). In summary, PACAP receptors seem to
have much wider distributions than their ligand PACAP, which suggests that the
biological functions of the peptide in different systems come from paracrine,
endocrine and neuronal sources.
1.8. Biological and Pharmacological Effects of PACAP
The distribution of PACAP and its receptors in a variety of systems implies
diverse biological functions. PACAP has been demonstrated to function as a
hormone, a neurohormone, a neurotransmitter, and a trophic factor in different
systems. In the hypothalamus, with the highest density of PACAP and its
receptors (Arimura, 1992; Arimura and Shioda, 1995), PACAP functions as a
hypophysiotropic factor, a neurohormone, a neurotransmitter and
neuromodulator. There is evidence that PACAP increases GnRH, somatostatin,
and CRH gene expression in the hypothalamus (Agarwal et al., 2005; Bredow et
al., 1994; Grinevich et al., 1997; Kageyama et al., 2007). PACAP could influence
food intake by transmitting leptin signals to proopiomelanocortin neurons in the
ventrolateral aspect of the arcuate nucleus (ARC) (Mounien et al., 2009).
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Circadian rhythms are also influenced by PACAP as evidenced by daily
variations of PAC1-R mRNA expression in the suprachiasmatic nucleus (SCN)
and supraoptic nucleus (Cagampang et al., 1998; Gillette and Mitchell, 2002). In
the rat pineal gland, there are circadian differences as well, which suggests
PACAP may regulate melatonin production (Fukuhara et al., 1998). The
stimulation of PACAP on melatonin secretion has been demonstrated both in
vitro and in vivo. PACAP regulates circadian rhythms indirectly through
hypothalamus and neurotransmitter glutamate as well (Hannibal et al., 2001;
Rekasi and Czompoly, 2002).
During the development of the CNS, PACAP may modulate neuronal cell
proliferation, cell survival, cell migration and cell differentiation as a neurotropic
factor. In the adult brain, PACAP protects injured neurons from apoptosis,
indicating a potential target for the treatment of stroke or neurodegenerative
diseases (Vaudry et al., 2009). PACAP is also involved in the regulation of nonneuronal tissues including cell proliferation, plasticity, glycogen metabolism, and
release of neurotropic factors from glial cells. There is little endogenous PACAP
in glial cells; therefore, these cells may be regulated by PACAP from nearby
neurons or within the circulatory system (Vaudry et al., 2009).
PACAP also plays an important role in the other systems outside the CNS.
The ability of PACAP to stimulate cAMP formation regulates the synthesis and
secretion of many hormones in endocrine glands, like the pituitary, thyroid and
adrenal glands (Arimura and Shioda, 1995; Christophe, 1993; Nussdorfer and
Malendowicz, 1998). PACAP increases thyroxine secretion in the human and
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porcine thyroid. The secretion of many pituitary and adrenal hormones are also
influenced by PACAP exposure. The gonads have been demonstrated to contain
high concentrations of PACAP and its receptors, especially the testis which
contains the highest concentration of PACAP in mammals (Arimura et al., 1991).
Subsequent studies demonstrate that PACAP may help sperm maturation and
penile erection, and accelerate testicular aging in the male (Gozes and Fridkin,
1992; Hedlund et al., 1995; Romanelli et al., 1997). In the ovary, PACAP is
involved in progesterone production, follicular apoptosis and female fertility
(Shintani et al., 2002; Zhong and Kasson, 1994). In the gastrointestinal tract,
PACAP is present in exocrine glands and neuronal structures (ganglia, fibers)
and stimulates the secretion of saliva, gastric acid and bicarbonate directly and
also increases the release of some regulatory peptides including gastrin,
somatostatin, atrial natriuretic factor and PYY to regulate the system indirectly. In
addition, PACAP regulates smooth muscles of the gastrointestinal tract with
tissue specific effects on motility (Vaudry et al., 2009). PACAP and its receptors
are also involved in regulation of smooth muscles within the respiratory and
cardiovascular systems. PACAP is also detected in immune cells, where it has
been shown to exert protective anti-inflammatory actions in many different
autoimmune models (Abad et al., 2001; Gomariz et al., 2006). Both endogenous
and exogenous PACAP affect T cell responses through direct or indirect actions
suggesting PACAP could be a target for immune system drug therapy (Delgado
et al., 1999; Gonzalez-Rey et al., 2007; Tan et al., 2009). PACAP and its
receptors are also detected in pathological tissues including various kinds of
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tumors, and many studies demonstrate either stimulatory or inhibitory effects on
tumor cells. Therefore, PACAP agonists and/or antagonists may aid in the
treatment of tumors depending on the specific type (Fruhwald et al., 1999).
2.

General introduction of HPG axis
In the classical view, the HPG axis is organized in three levels including

GnRH neurons in hypothalamus, gonadotrophs in the pituitary and the gonads
including the testis and ovary (Fig. 3). GnRH neurons synthesize and secrete a
peptide hormone, GnRH, and GnRH receptors are localized on pituitary
gonadotrophs. Therefore, GnRH, its receptor and intracellular transduction in
gonadotrophs build the fundamental regulating pathway of HPG axis to
synthetize and secret the gonadotropins.

Figure 3. Schematic of the Hypothalamus-Pituitary-Gonadal axis.
GnRH, gonadotropin-releasing hormone; FSH, follicle-stimulating hormone; LH,
luteinizing hormone.
13

The gonadotropins, FSH and LH, are both dimeric glycoprotein hormones
composed of a -subunit and a -subunit. FSH and LH share the common subunit whereas the -subunits distinguish the two gonadotropins. In the male,
LH regulates testicular Leydig and Sertoli cells to stimulate production of
testosterone and androgen-binding protein, respectively. FSH binds to its
receptors on Sertoli cells to promote spermatogonia proliferation and germ cell
meiosis and postmeiotic development. In the female, LH induces ovarian thecal
cells to produce androgens and the granulosa cells of the preovulatory follicle to
secret progesterone during the terminal stages of follicular growth. FSH
stimulates expression of aromatase enzymes that convert androgens to estradiol
in ovarian granulosa cells.
Many investigators have utilized different animal models, containing both
spontaneous and experimental mutations, to dissect the functional organization
of HPG axis. The hypogonadal (HPG) mouse model, in which the gene encoding
GnRH precursor is deleted, never enters puberty and displays a persistent
hypogonadotropic-hypogonadal phenotype (Mason et al., 1986). Surgical
disconnection between the hypothalamus and pituitary in sheep decreases
pituitary gonadotropins and causes secondary hypogonadism (Clarke et al.,
1983). These results, and others, demonstrate that GnRH is critically important
for the maintenance of biological functions of the HPG axis. Male and female
LH or LH receptor deficient mice are infertile because of marked decreases in
gonadal steroid hormones, which induce defective spermatogenesis and late
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follicular development (Ma et al., 2004; Zhang et al., 2001). FSH and FSH
receptor knockout mice also have defects in reproductive system in both genders.
However, there are some differences among the mutants. Female FSH
knockout mice are infertile due to a defect in ovarian follicular maturation,
whereas the males are still fertile with smaller testes and fewer sperm cells
(Kumar et al., 1997). The female FSH receptor knockout mice have a similar
phonotype as FSH deficient mice. FSH receptor deficiency induces more
serious problems in males than FSH deficiency. FSH receptor null mice have
significant decreases in Leydig cell numbers and testosterone levels (Abel et al.,
2000; Kumar et al., 1997).
There are both positive feed-forward and negative feedback mechanisms
in the HPG axis at different levels. Gonadal steroid hormones provide important
feedback regulations of hypothalamic GnRH. In the male, testosterone exerts a
negative feedback that may be mediated through the level neurons (Herbison et
al., 1996; Tilbrook and Clarke, 2001). Gonadotropins also show a minor negative
feedback on GnRH as well (Tilbrook and Clarke, 2001). In female, the feedback
regulations from gonadal hormones (estrogen, progesterone) are more complex
including negative and positive effects depending on the stage of the
reproductive cycle (Glidewell-Kenney et al., 2007; Petersen et al., 1995;
Petersen et al., 2003). In addition to gonadal hormones, the peptide hormones,
inhibin, activin and follistatin, regulate the gonadotropins, primarily FSH, through
the feedback mechanism. For instance, activin has been shown to work in a
paracrine manner to induce FSH expression in rat pituitary cells, while gonadal

15

derived inhibin is a competitive inhibitor of activin. Follistatin is also produced
within the pituitary and can bind with activin and blocks its activity by preventing
receptor interaction. (Gregory and Kaiser, 2004; Nakamura et al., 1990).
3. PACAP in HPG axis
The previous section introduced the classical model describing the HPG
axis. PACAP and its receptors are detected throughout the HPG axis suggesting
that PACAP is involved in the function and regulation of the HPG axis. The
actions of PACAP on HPG axis are at all three levels. In the hypothalamus,
studies have revealed that PACAP stimulates synthesis and secretion of GnRH.
For instance, intracerebroventricular injection (i.c.v) of PACAP increases GnRH
mRNA level in rat hypothalamus while PACAP treatment increases GnRH
release from mouse clonal GnRH cells (Li et al., 1996; Olcese et al., 1997).
However, i.c.v administration of PACAP into the hypothalamus of ovariectomized
ewes decreased LH secretion and LH pulse frequency (Anderson et al., 1996;
Sawangjaroen and Curlewis, 1994). In adult female rats and mice, steroids are
found to regulate the expression of PACAP mRNA in the ventromedial nucleus
(Apostolakis et al., 2004), where PACAP mediates progesterone-evoked sexual
behavior through PAC1-R (Apostolakis et al., 2005).
The gonadotropins, LH and FSH, are produced and secreted from
gonadotroph cells in the anterior pituitary gland. In the classic view, gonadotropin
secretion is predominantly regulated by GnRH as previously described (Charlton,
2008). However, gonadotropins are still present in GnRH deficient mice
(Cattanach et al., 1977). This implies that GnRH is a key regulator but not the
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only player in gonadotroph function. Subsequent studies have demonstrated that
PACAP acts either alone or synergistically with GnRH to stimulate LH and FSH
mRNA expression through direct and/or indirect mechanisms. For instance, intraatrial injection of PACAP increases plasma LH level in the male rats (Osuga et al.,
1992). Treatment of rat anterior pituitary cells with PACAP induces stimulation of
gonadotropin release through calcium elevation (Rawlings et al., 1994; Tsujii et
al., 1994). The effect of PACAP on gonadotropin synthesis involves the
cAMP/PKA pathway, whereas its acute action on FSH/LH secretion is under the
control of calcium elevation. Besides its direct action on gonadotropin release,
PACAP has also been shown to increase rat GnRH receptor gene promoter
activity through the cAMP/PKA pathway. Conversely GnRH can stimulate
PACAP gene expression. Furthermore, GnRH agonist can inhibit PACAPinduced cAMP production by phosphorylation of PAC1-R through the PKC
pathway, illustrating the complex interplay between GnRH and PACAP in the
regulation of gonadotroph cell functions.
PACAP and its receptors are observed in the gonads and the testis has
the highest level of PACAP of any of the biological systems suggesting that the
peptide may operate as a local regulator of gonadal activity. Interestingly, the
PACAP gene in the testis has a shorter promoter than in other tissues (Daniel
and Habener, 2000). Testis PACAP levels are dramatically reduced by
hypophysectomy and are restored by FSH administration, which indicates that
the expression of PACAP in testis is regulated by pituitary gonadotropins
(Romanelli et al., 1997; Shuto et al., 1995). PACAP has been demonstrated to
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stimulate testosterone secretion in isolated rat Leydig cells (El-Gehani et al.,
1998; Rossato et al., 1997). Compared to the testis, the ovary contains much
less PACAP. However, many investigations indicate that PACAP is also involved
in the reproductive function of female mice. For example, in female rats,
granulosa and cumulus cells from large pre-ovulatory follicles contain PACAP
mRNA, and PACAP increases progesterone production in cultured grandulosa
cells (Barberi et al., 2007; Gras et al., 1996). Furthermore, PACAP deficient
female mice have decreased fertility with demonstrating behavioral, ovulatory
and implantation defects (Isaac and Sherwood, 2008; Sherwood et al., 2007;
Shintani et al., 2002).
4. Differential regulation of gonadotropins during development
Although LH and FSH are both stimulated by GnRH secreted from
hypothalamus, their expressions are not always parallel during development. At
the mid gestation, serum levels of LH are nearly ten-fold higher than FSH
(Debieve et al., 2000). The human fetal plasma LH levels are 25 to 100-fold
higher than FSH during gestation whereas the LH:FSH ratio is only 1 to 0.5 in the
adult (Siler-Khodr and Khodr, 1980). The differential regulation of the
gonadotropins is also a characteristic of fetal development in male rodents.
Previous studies detected LH as early as embryonic day 12 (E12) whereas
could not observe FSH until E19 or E21 (Aubert et al., 1985; Nemeskeri et al.,
1986; Nemeskeri et al., 1984). Similar temporal expression pattern of LH and
FSH is observed in mouse pituitary development (Japon et al., 1994). The later
and lower FSH levels than LH during embryonic days may be essential for an
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appropriate hormonal environment of reproductive system. Why FSH expression
should be repressed during embryonic days could be explained by the function of
FSH during reproductive system development. Within the developing rat testis,
FSH induces testosterone production from 5 -reduced steroids, which are
essential for sexual differentiation of the CNS (McEwen, 1983; 1992). FSH can
also suppress the production of muollerian inhibiting hormone (MIH), which is a
key factor to form the male reproductive tract (Bercu et al., 1979; Kuroda et al.,
1990). Furthermore, the primary effect of FSH is to stimulate Sertoli cell and
prepare the testes for spermatogenesis in adulthood. Therefore, the repression
of FSH during embryonic days may play a role to prevent maturation of the
testes. Male mice with overexpression of FSH under the regulation of the
metallothionein-1 promoter in pituitary are infertile due to disrupted sexual
behavior (Gorski, 2002; Kumar et al., 1999). Lager seminal vesicles and higher
circulating testosterone levels may alter sexual maturation and reproductive
behavior during the perinatal period. All these evidences suggest the importance
of the repressed FSH expression in the fetal pituitary. The follistatin-activininhibin axis is demonstrated to specifically regulate FSH expression in pituitary
(Carroll et al., 1989). Therefore, these three peptides are the candidates for the
differential regulation of FSH in the male fetus as in the adult. However, bioactive
forms of inhibin are not detectable within rat testes until birth (Phillips, 2000), and
expression of activin in testes and pituitary has no changes during development
(Gregory and Kaiser, 2004). Thus, follistatin is suggested as a factor contributing
to the selective suppression of FSH during fetal development, and our previous
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studies provided evidence. Follistatin as well as PACAP expression levels are
high in the embryonic male pituitary and decline significantly after birth when
FSH mRNA levels increase dramatically (Moore et al., 2009a). Therefore, we
hypothesize that FSH levels are suppressed by high concentration of follistatin
induced by PACAP in embryonic male pituitary. To demonstrate the hypothesis,
we designed both in vivo and in vitro experiments to answer three questions:
Which cell types express PACAP and the PACAP specific receptor, PAC1-R, in
the perinatal pituitary; whether PACAP stimulates follistatin expression in pituitary
and if alterations in developmental pituitary PACAP expression can modify the
developmental pattern of gonadotropin expression; and, Which factors may
regulate pituitary PACAP expression levels.
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CHAPTER TWO

PACAP AND PAC1-R EXPRESSION IN PITUITARY GONADOTROPHS

1.

Introduction
PACAP was originally identified as a hypothalamic hypophysiotropic

peptide with a high expression level in hypothalamus (Arimura et al., 1991;
Miyata et al., 1989). PACAP mRNA was detected within the pituitary of
embryonic rats by in situ hybridization (Jaworski and Proctor, 2000; Skoglosa et
al., 1999). Furthermore, our previous studies demonstrate for the first time that
pituitary expression of PACAP is very high in the fetus, and declines dramatically
after birth (Moore et al., 2009a). PACAP has been demonstrated to regulate GSU, LH and FSH mRNA levels in the cultured pituitary cells (Tsujii and
Winters, 1995b). However, very few details about PACAP expression during
development in pituitary gonadotrophs have been documented. The anterior
pituitary is derived from oral ectoderm and forms Rathke’s pouch (Takuma et al.,
1998). In the adult rat anterior pituitary, approximately 50% of the cells are
somatotrophs that are primarily located in the lateral wings of the anterior lobe
and producing growth hormone. Prolactin (PRL)-secreting lactotrophs represent
~15% of cells in the anterior pituitary and are randomly distributed through the
lobe. Corticotrophs comprise about 15% of anterior pituitary cells (Nakane,
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1970). Gonadotroph cells represent up to 10% of the human anterior pituitary cell
population. Thyrotrophs are the least abundant cell type in the anterior pituitary,
comprising ~5% of the total cell population, and are mostly found in the anteriormedial portion of the gland. There are many supporting and or nonneuroendocrine cells including follicular and folliculostellate cells throughout the
anterior pituitary. We utilized single cell real-time PCR to determine which
pituitary cell type expresses PACAP. Furthermore, we want to reveal whether
there are changes of cell types with PACAP during development.
The specific receptor of PACAP, PAC1-R, is expressed in anterior pituitary
as well (Vigh et al., 1993). PAC1-R binds with PACAP and initiates intracellular
signaling through cAMP/PKA as well as PKC/MAPK pathways (Fowkes et al.,
2001; Spengler et al., 1993). Furthermore, differential expression of the variants
of PAC1-R might influence the potency of PACAP signaling. Thus, we examined
the expression pattern of PAC1-R isoforms in both gonadotroph cell lines and
developing rat pituitary by combined semi-quantitative PCR and restriction
enzyme analysis.
2.

Methods and Materials

2.1. Animals
Timed-pregnant Sprague-Dawley rats were purchased from Charles
Rivers Laboratories, and were housed at least one week with free access to rat
chow and water in accordance with the NIH Guide for the Care and Use of
Laboratory Animals according to a protocol approved by the Animal Care and
Use Committee of the University of Louisville.
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2.2. Immortalized Cell Culture
Mouse T3 and L T immortalized mouse pituitary gonadotroph cells were
kindly provided by Dr. Pamela Mellon (University of California, San Diego, CA).
T3 cells were grown in Eagle’s Minimal Essential Medium (MEM) containing
glucose (4.5g/L), NaHCO3 (2.2g/L) and HEPES (5.96g/L), with penicillin,
streptomycin, and fluconazole, and supplemented with 10% fetal bovine serum
(FBS). L T2 cells were grown in Dulbecco’s MEM (DMEM) containing HEPES
(22.5mM), NaHCO3 (40mM), 10% charcoal-stripped FBS, penicillin,
streptomycin, and fluconazole. Both cell lines were grown in 6 wells plate and
used for experiments after 50%-70% confluence.
2.3. Primary cell culture
E19 pregnancy rats were sacrificed utilizing CO2, then the pups were
removed and placed into ice-cooled 1

PBS. Pituitaries from E19 and PN1 pups

were dissected and placed in HEPES buffer without BSA on ice before treatment
with 0.25% trypsin in a 15 ml Falcon tube in 37° water incubator for 5 minutes,
with intermittent dispersal with a siliconized pipette. Treated pituitaries were
pipetted up and down till tissue fragments were invisible. The tube was
centrifuged for 10 minutes at 500

g. Suspension was discarded and replaced

with 5 ml fresh DMEM with 10% FBS to wash the cells. Centrifuge again for 10
minutes at 500

g. The cells were suspended in 5 ml DMEM then cultured in 5

cm dishes for 24 hours before the experiments. All the glass pipets used were
coated overnight by SIGMACOTE (SIGMA. CO).
2.4. RNA extraction and reverse transcription
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Total RNA was prepared from cultured T3, L T2 cells or male rats
pituitary samples using QIGEN RNAeasy Kit following the instruction of
manufacturer. Sample purity was determined by Nano-drop from Thermo
(Wilmington, DE). 1 g total RNA from every sample was reverse transcribed
using Superscript III reverse transcriptase (Invitrogen, CA) primed with oligo(dT)
following the instruction from Invitrogen.
2.5. Real-time PCR
The cDNA samples were amplified in parallel by PCR with a Stratagene
MX3005P Multiplex Quantitative PCR System (Stratagene, La Jolla, CA) using
the Brilliant SYBR Green QPCR Master Mix and specific primers. Accumulation
of PCR product was monitored in real time, and the crossing threshold (Ct) was
determined using Mx-pro software.
2.6. Laser Capture Microdissection
The head part tissues from E14 to PN10 rats were placed in desired
orientation in cold Cryomold (Fisher Co, PA) with a thin layer of OCT on the
bottom. Then, the specimen was covered with OCT then mounted to holder of
microtome. Once the specimen and cryostat of microtome were temperature
equilibrated, the specimens were cut to 10 m sections. The sections were
stained with hematoxylin and thoroughly dehydrated using gradient concentration
ethanol. Under the microscope, the tissue section is viewed through the glass
slide and specific areas are identified. When the pituitary is in the field of view, a
near IR laser diode integral with the microscope optics is utilized. The pulsed
laser beam activates a precise spot on the transfer film immediately above the
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cells of interest. At this location the film melts and fuses with the underlying cells.
The film with the bonded cells is then lifted off the section, leaving all unwanted
cells behind. This allows targeted dissection of pituitaries to be pooled for RTPCR analysis. RNA from the LCM samples was isolated utilizing the PicoPure
RNA isolation kit from Arcturus following the manufacturer’s protocol. Briefly,
transfer film caps are placed onto microfuge tubes containing RNA extraction
buffer, inverted, and incubated at 42° for 30 minutes. Next, 70% ethanol is added
to the extraction buffer-sample solution and passed through a pre-conditioned
purification column by centrifugation. The purification membrane is washed and
the RNA is eluted with buffer.
2.7. Single cell PCR
The cells from E19 and PN1 rat pituitary cell cultures were picked using
glass pipettes, which were made from 0.5 mm borosilicate glass (Sutter
Instrument, CA) using micropipette puller (Model P-30). The selected cell was
placed into a 0.5 ml eppendorf tube and put on dry ice immediately. To each tube
we added 10mM dNTP(1 l), oligo(dT)(1 l), RNAse inhibitor(1 l), 5×First strand
buffer(4 l), ddH2O(11 l) and Superscript III(1 l). All the cell samples were plated
on a thermocycler using the standard reverse transcription protocol. After then,
the mixture was ready to use as the template of PCR.
3.

Results

3.1. PACAP expression in Gonadotroph cell lines
There are two immortalized gonadotroph cell lines; T3 and L T2 cells,
each derived from pituitary gonadotroph tumors that developed at different
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developmental stages in mice. The tumor from which the T3 cell line was
derived from a tumor formed during prenatal development of the donor mouse.
Conversely, L T2 cells were derived from a postnatal formed mouse pituitary
tumor. The different cell lines have previously been demonstrated to represent
different developmental stages in gonadotroph maturation (Turgeon et al., 1996).
We collected RNA samples from both cell lines and examined PACAP mRNA
expression levels. T3 cells express a relative higher level of PACAP than L T2
cells, in which PACAP mRNA is almost undetectable (Fig. 4). This result is
similar to our previously reported findings that PACAP mRNA expression is high
in the fetus, and declines substantially after birth (Moore et al., 2009a).

+ GnRH

PACAP

+ GnRH

GAPDH

T3

L T2

Figure 4. PACAP mRNA level in T3 (left) and L T2 (right) cells.
Total RNA (1 g) was isolated from cultured T3 and L T2 cells. PACAP mRNA
expression levels were measured by semi-quantitative PCR after reversetranscription. Housekeeping gene (GAPDH) mRNA levels descripted the same
amount of total RNA in all samples. GnRH (10nM) treated L T2 cell samples
were the positive controls.
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3.2. PAC1-R expression in Gonadotroph cell lines

Figure 5. Expression pattern of PAC1-Rs (A,B) in gonadotroph cell lines.
The total PAC1-R (A) and PAC1-R variants (B) mRNA expressions were
measured by semi-qauntitative PCR and restriction enzyme after RNA extraction
and reverse-transcription (1 g RNA every sample). The specific PAC1-R primers
and cleavage sites of enzymes are showed in C.

PACAP signaling within the gonadotrophs could also be developmentally
regulated by alterations in the expression of PACAP receptors. Although there
are three PACAP receptors, VPAC1, VPAC2 and PAC1R, PAC1-R is the only
one specific for PACAP. PAC1-R has at least six variants resulting from
alternative splicing in the third intracellular loop region (Spengler et al., 1993).
The splice variants are characterized by the absence (short variant) or presence
of either one or two cassettes of 28 amino acids (hip or hop1 variant) or 27 amino
acids (hop2 variant) (Spengler et al., 1993). T3 and L T2 cells express similar
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PAC1-R variants (Fig. 5A). However, they still have some differences. We found
that T3 cells contain significantly more Long form than Short form while in L T2
cells they were in similar amount. The expression of Hip form was almost
undetectable in either T3 or L T2 cells (Fig. 5B) whereas the Hop form
dominated in both cell lines (Fig. 5B). Real-time PCR was also utilized to detect
variants of PAC1-R, with similar results (data not show).
3.3. PACAP expression in Pituitary cells
We analyzed PACAP mRNA expression during development, and a
significant decline happened after birth in male rat pituitary (Moore et al., 2009a).
We cultured E19 and PN1 rat pituitary cells and picked single cells for qualitative
PCR analyses. We designed specific primers for every cell type, and analyzed
PACAP distribution in these cells. The results were summarized in following
table. Although PACAP mRNA level in PN1 pituitary was less than E19, the
pattern of expressing cell types didn’t change much. PACAP mRNA in pituitary
was mainly produced by gonadotroph cells.
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PACAP
Of These

E19
14 (9.5%) of 146 cells

PN1
17(14.3%) of 119 cells

8 (57.1%) cells LH+

8 (47.1%) cells LH+

1 (7.1%) cells S100+

1 (5.9%) cells S100+

0

cells PRL+

2 (11.8%) cells PRL+

0

cells ACTH+

2 (11.8%) cells ACTH+

1 (7.1%) cells GH+

1 (5.9%) cells GH+

2 (14.2%) cells TSH+

1 (5.9%) cells TSH+

Table 1. Distribution of PACAP in different type cells of rat pituitary gland.
The cell types of PACAP positive cells were determined by real-time PCR from
single cell samples. E19 and PN1 rat pituitary cells were cultured for 24 hours
before experiment.
3.4. PAC1-R mRNA expression in rat pituitary
We also looked at PAC1-R expression during development of male rat
pituitary gland. Because pituitary glands are tiny in embryos, LCM was utilized to
collect E14-PN10 tissues, and then total RNA was extracted from these samples
following the manufacturer’s instructions. Through semi-quantitative results, we
observed a decline of PAC1-R-Short form after birth (Fig. 6A). Furthermore, we
analyzed the Long form of PAC1-R in these tissues. Hop1/Hop2 form was always
the main variant during development (Fig. 6B). To confirm the results, we chose
the time point with most of our attentions, E19 and PN1. The pituitary gland
samples in E19 and PN1 male rats, which were collected by traditional method,
showed the same results (Fig. 6C).
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Figure 6. PAC1-R mRNA expression pattern during rat pituitary development.
PAC1-R (A) and its variants (B.C) were analyzed by semi-quantitative PCR after
reverse-transcription.

4. Discussion and Future Investigations
PACAP is a novel factor found to regulate synthesis and secretion of
gonadotropins in cultured pituitary cells. However, very little was known about
pituitary PACAP expression during development before our group first
discovered dramatic decrease of pituitary PACAP levels after birth (Moore et al.,
2009a). To find further evidences to support functions of PACAP in pituitary
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gonadotrophs, we examined expression patterns of PACAP and its specific
receptor, PAC1-R, in both gonadotroph cells and developing rat pituitary.
In the two different gonadotroph cell lines, both PACAP and PAC1-Rs
mRNA expressions were much higher in T3 cells than in L T2 cells. At the
same time, our previous studies revealed the dramatic decline of PACAP mRNA
after birth (Moore et al., 2009a). All the data suggested that two gonadotroph cell
lines represented different developing periods of gonadotrophs. Thus, the T3
and L T2 cell lines are useful in vitro models for studies on developing
gonadotrophs. In future experiments, we could choose either more mature L T2
or immature T3 cells for in vitro researches depend on our hypotheses and
targeting development stages.
After PAC1-R had been cloned in many species, six variants resulting
from alternative splicing in the third intracellular loop region were identified in rats
(Journot et al., 1994; Spengler et al., 1993). Different variants may be temporal
and/or spatially regulated in different cell types and mediate different pathways.
For instance, the Hip cassette impairs AC stimulation and abolishes
phospholipase C activation, which was in opposite of observed PACAP functions
(Dickson and Finlayson, 2009). We demonstrated that Hop form and Short form
were the dominant variants in both gonadotroph cell lines and rat pituitary gland,
which suggests the most prominent PACAP pathways involved in the pituitary
gland. Thus, in the following experimental design we focused on
cAMP/PKA/CREB, cAMP/MAPK and PLC/PKC pathway analysis.
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Although PACAP expression in pituitary was well known for a while, the
type of PACAP positive cell is still less documented. The RT-PCR on single
pituitary cell indicated that most of PACAP positive cells were gonadotroph cells
in both E19 and PN1 rats. The data supported that the decline in PACAP mRNA
in pituitary gland after birth partially reflects a decline in PACAP expression in
pituitary gonadotrophs.
The expression of PACAP and PAC1-R in developing pituitary suggests
that PACAP may affect pituitary gland development. Furthermore, the result that
PACAP are demonstrated to mainly exist in gonadotrophs of pituitary particularly
implies that regulating gonadotrophs may be the main effect of PACAP. Different
with the dramatic decline of pituitary PACAP levels at birth, its receptor, PAC1-R,
only shows a decreased short subtype in postnatal period. The result suggests
possible different pathways mediating the differential regulation of gonadotropins
by PACAP.
Based on recent data, future investigations on PACAP and PAC1-R
expression in pituitary will still focus on single cell level. All endocrine cell types in
the pituitary express PAC1-Rs (Gottschall et al., 1990; Lam et al., 1990).
However, there are no data about the PAC1-R variants detail in different cell
types. The detailed developmental expression pattern and future specific
agonists or antagonists for variants could help drug design on pituitary related
endocrine-disorders.
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CHAPTER THREE

FUNCTION OF PACAP ON PITUITARY GONADOTROPHS

1.

Introduction
The name pituitary adenylate cyclase-activating polypeptide (PACAP) was

derived from the ability of this peptide to increase cAMP production in cultures of
rat pituitary cells (Miyata et al., 1989). In addition of this observation, subsequent
research found that PACAP stimulates the release of most pituitary hormones
from rat pituitary cells (Counis et al., 2007). Therefore, PACAP may be a novel
and important hypophysiotropic factor.
Mammalian gonadotropins, Luteinizing hormone (LH) and folliclestimulating hormone (FSH), play a critical role in the regulation of reproductive
development and function. Production of gonadotropins by pituitary
gonadotrophs is mainly under the control of the hypothalamic factor GnRH as
well as peripheral feedback mechanisms of gonadal hormones (Charlton, 2008).
However, gonadotropins exist in GnRH deficient mice, which show us that there
must be other important factors regulating the ontogeny and differentiation of
gonadotrophs.
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The effects of PACAP on gonadotropin secretion have been studied both
in vivo and in vitro. PACAP has a consistent stimulatory action in vitro whereas
effects in vivo are variable. For LH, i.v or i.c.v administration of PACAP38 in rats
showed some differences between male and female. PACAP38 increased LH
plasma levels in male (Osuga et al., 1992); however, it suppressed the
preovulatory LH surge in female (Koves et al., 1996). The function of PACAP on
the female rat has evidences demonstrating PAC1-R as a mediator (Choi et al.,
2000). The interest is that PACAP27 causes opposite effects on female rat, in
which PACAP27 increased circulating LH levels instead of inhibiting LH surge
(Kantora et al., 2000).
On the other side, PACAP also regulates gonadotropin gene expression
not just hormone release. In cultured rat pituitary cells, continuous PACAP
treatment combined with pulses of GnRH increases -subunit mRNA and LH
mRNA transcript length, which presumably prolongs its half-life. However, FSH
transcription was found to be reduced (Tsujii et al., 1994). On the other hand, the
pulsatile treatment of PACAP alone increased -subunit mRNA and LH mRNA
but no effects on FSH mRNA (Tsujii and Winters, 1995b).
In gonadotrophs, effect of PACAP is exerted through activation of PACAP
specific receptor, PAC1-R (Hezareh et al., 1996a). In Chapter two, the
gondotroph cell lines, T3 and L T2 cells, express PAC1-R. In particular, PAC1R Hop and Short form exist in gonadotroph cells, which indicated effect of
PACAP through PAC1-R have several different pathways, PKA, PLC and [Ca2+]
etc. (Bresson-Bepoldin et al., 1998; Hezareh et al., 1996b; Rawlings and
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Hezareh, 1996). Although these pathways all involved in gonadotropins release
and mRNA transcript, PACAP induced cAMP production appears to be more
important in the synthesis than release (Sherwood et al., 2000).
In addition to the direct effects of PACAP on gonadotroph cells,
sometimes the actions of the peptide on gonadotropins could be mediated
through indirect mechanisms. In the cultured pituitary cells and mouse clonal
gonadotroph cells, exposure to PACAP reduced FSH mRNA levels may relate
to the increase in follistatin expression (Katayama et al., 2000; Winters et al.,
1997).
In spite of all that is known about PACAP actions in gonadotrophs, we still
lack the information about PACAP in the in vivo regulation of gonadotrophs and
reproductive function. During sexual maturation in the male rat, expression and
secretion of LH and FSH is not parallel. LH keeps a relatively constant level in
the circulation from birth to adults. However, FSH levels remain at a low level
until PN15 then begin to climb to a peak value at PN38. To investigate the role of
PACAP signaling in the regulation of gonadotropin synthesis and secretion
during male rat sexual maturation, we implanted micro-pumps containing PACAP
antagonist (6-38) or PACAP38 into PN16 male rats and evaluated serum and
pituitary gonadotropins levels after 3, 5 and 7 days of treatment. If PACAP is
involved in regulation of FSH during sexual maturation, the treatment of prepubertal male rats with PACAP or the PACAP antagonist should change the FSH
levels in serum and/or pituitary. In addition, to demonstrate the hypothesis that
PACAP regulates FSH through a follistatin-activin mediated mechanism, we
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evaluated the follistatin levels in the pituitary of experimental animals. Finally, we
utilized a mouse model of pituitary PACAP overexpression and performed genechip analyses to screen the pituitary genes regulated by PACAP.
2.

Methods and Materials

2.1. Animals
Timed-pregnant Sprague-Dawley rats were purchased from Charles
Rivers Laboratories, and were housed with free access to rat chow and water in
accordance with the NIH Guide for the Care and Use of Laboratory Animals
according to a protocol approved by the Animal Care and Use Committee of the
University of Louisville.
2.2. Immortalized Cell Culture
Mouse L T2 immortalized mouse pituitary gonadotroph cells were kindly
provided by Dr. Pamela Mellon (University of California, San Diego, CA). L T2
cells were grown in Dulbecco’s MEM (DMEM) containing HEPES (22.5mM),
NaHCO3 (40mM), 10% charcoal-stripped FBS, penicillin, streptomycin, and
fluconazole. The cell lines were grown in 6 wells plate and used for experiments
after 50%-70% confluence.
2.3. Micro-Osmotic Pumps implantation
The ALZET micro-osmotic pumps were used to implant intraperitoneal into
five PN16 male rats. There were three groups of pumps, which were filled with
100 l 1-38/BSA, 6-38/BSA and BSA only respectively and final concentration
was 2 g/ml. For intraperitoneal placement, we made a small midline incision in
the skin below the rib cage of an animal and another small incision in the
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abdominal muscle. The pump was inserted, flow moderator first, into the
peritoneal cavity. The muscle incision was closed with sutures, and then the skin
incision was closed with a wound clip. After three, five or seven days, animals
were sacrificed for serum and pituitary samples.
2.4. Cell Transfection
L T2 cells were plated in 6-well plates, and grow to 50%-70% confluence.
The mixture was incubated at room temperature for more than 30 minutes before
adding 120 l to every well. The plates were gently swirled and continue
incubated at 37

for 20 -24 hours. L T2 cells were transfected with Fugene 6

(Roche Applied Science, Indianapolis, IN). The transfection mixture was
containing DMEM without serum, 3 l Fugene 6 and 1 g plasmid DNA every well,
and incubated for 20 minutes at room temperature. 100 l of mixture was added
to every well in a drop-wise manner. The plates were continuing incubated for 20
- 24 hours.
2.5. FSH and LH ELISA
The blood samples from experiment animals were collected into the dry
tubes. The serum separated from the red blood cells was assayed immediately.
a. Dispense 25

propriate wells.

b. Dispense 25
c. Add 200

gate (CONJ HRP) into each well.

d. Incubate for 180 minutes at room temperature without shaking.
e. Flick out the contents of the wells over a basin containing bleaching
water or aspirate with an automated plate washer.

37

f. Wash the wells 7 times with an automated system set to 25
or by adding 250
absorbent paper to remove any residual liquid after each washing.
g. Dispense 200

chromogenic substrate (SUBS TMB) solution into

each well, ensuring that it is initially pale colored.
h. Incubate for 30 minutes at room temperature without shaking.
i. Stop the reaction by adding 50

each

well.
j. Place the plate on a flat surface, swirl gently to mix contents.
k. Measure the absorbance at 450 nm on a 96 well micro-plate reader.
2.6. Genotype of TG-mice
Genotyping was performed by real-time PCR using DNA isolated from the
tails of 2- to 4-week-old mice using heat-shock method. The 5’ primer is derived
from the mouse GSU-subunit promoter, and the 3’ primer is derived from rabbit
-globin cDNA sequences: 5' primer, 5'- AAATCCAGAGACATTGTTCCC -3'; and
3' primer, 5'- AATCAAGGGTCCCCAAACTC -3' Using real-time PCR to identify
transgenic mice.
2.7. 2 -

T

Method for analyzing Real-time PCR results

The 2 -

T

Method is a convenient way to analyze the relative changes in

gene expression from real-time quantitative PCR experiments (Livak and
Schmittgen, 2001).
2.7.1. Derivation of the 2 -

T

Method
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Exponential amplification of PCR: Xn= X0

(1+Ex)n Xn is the Number of

target molecules. n is the cycle number. Ex is the efficient of target amplification.
XT is the threshold number of target molecules. CT,X is the threshold cycle
for target amplification, and KX is a constant. Similar, we have RT, CT,R and KR for
reference molecules. Thus, we have following two equations:
XT = X0

(1+EX)CT,X = KX

RT = R0

(1+ER)CT,R = KR

Dividing XT by RT gives the expression

We used the same reagent and run all the groups in the same machine at
the same time. Thus, we assumed efficiencies of the target and the reference are
the same. EX=ER=E,
then

or

The Final step is to divide the XN for any sample q by the XN for the calibrator:

For amplifications designed to be less than 150 bp and for which the
primer and Mg2+ have been properly optimized, E is close to 1. Therefore, the
amount of target, normalized to an endogenous reference and relative to a
calibrator, is given by

(Livak and Schmittgen, 2001).

2.7.2. Following is a sample table of data analysis using the method.
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Treat

PACAP average
CT

GAPDH
average CT

VEH

28.04±0.30

16.09±0.08

11.95±0.31

0±0.31

28.15±0.44

15.55±0.05

12.61±0.44

0.66±0.44

30.00±0.40

16.46±0.25

13.54±0.47

1.60±0.47

T

T

BIM
BIM

Fold
1
(0.83-1.21)
0.64
(0.52-0.77)
0.33
(0.31-0.36)

2.8. Microarray analysis
The microarray analysis was performed at the University of Louisville
Microarray Core Facility according to instructions from Affymetrix (Santa Clara,
CA). mRNA was converted into double stranded cDNA using a T7-oligo (dT)
promoter primer sequence. The double-stranded cDNA was purified and served
as a template in the subsequent in vitro transcription reactions. The in vitro
transcription reactions were carried out in the presence of T7 RNA polymerase
and a biotinylated nucleotide analog/ribonucleotide mix for cRNA amplification.
The biotinylated cRNA was purified, fragmented, and used in the hybridization
cocktail containing control oligonucleotide B2 and four control bacterial and
phage cDNA (BioB, BioC, BioD, cre). The labeled cRNA was hybridized to the
Mouse Genome 430 2.0 Array (Affymetrix, CA), using the protocol provided by
Affymetrix. The Mouse Genome 430 2.0 Array is comprised of over 45,000 probe
sets representing over 21,000 well-substantiated mouse genes. The sequence
clusters were created from the UniGene database (Build 107, June 2002) and
then refined by analysis and comparison with the publicly available draft
assembly of the mouse genome from the Whitehead Institute for Genome
Research (MGSC, April 2002). Alterations in RNA transcript levels were analyzed
using Partek Genomics Suite 6.2 (Partek Inc., St. Louis, MO). Three different
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experiments were performed for statistical analysis. Data analysis was performed
using Partek Genomics Suite 6.2 (Partek Inc., St. Louis, MO). The Affymetrix
probe level signal values were summarized using the RMA algorithm. Statistically
significant changed genes were identified by analysis of variance (ANOVA) with
FDR-corrected p-values < 0.05. The contrast between wild type and GSUPACAP mice yielded no significantly different in genes based on these
parameters. Two-way ANOVA tests were carried out to identify differentially
expressed genes in the comparison of wild type and GSU-PACAP mice, taking
treatment and batch effect for the triplicate sample processing into account. The
genes that showed 2-fold induction or 2-fold suppression were transferred to
separate up and down lists, respectively. The gene sets with an FDR corrected
p-value of less than 0.05 were identified in these lists and Ingenuity Pathway
Analysis software (Ingenuity Systems Inc., Redwood City, CA) was used to
interpret the interactive pathway networks between the selected genes from the
microarray data.
2.9. Statistical Analysis
All the luciferase assays and real-time PCR data were performed with
triplicate samples and repeated at least three times. Values were expressed as
mean ±SEM. Statistical analysis was performed using ANOVA and post Tukey’s
test if necessary. P<0.05 was considered statistically significant.
3.

Results

3.1. FSH and LH levels in developing immature male rats
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In male rats serum FSH levels are low at PN17 and increase significantly
beginning at PN19 (Fig. 7A). By PN29, the serum level of FSH was two-fold
higher than the PN17 value. A similar increase was observed in the pituitary
FSH mRNA levels during the same period (Fig. 7B). However, the serum LH
levels remained relatively constant (Fig. 7A) but showed a small increase at
PN29. Likewise, no significant increase happened till PN29 for LH mRNA levels
(Fig. 7B). The results are consistent with previous research showing that FSH
and LH levels are not parallel with each other during this period of development.
3.2. PACAP and Fst-288 mRNA levels in developing immature male rats
To evaluate whether a relationship exists between expression of PACAP
and follistatin and gonadotropins during the period, qRT-PCR was performed
using pituitary RNA isolated from PN17 to PN29 immature male rats. PACAP
mRNA concentrations decreased significantly by 4-fold (Fig. 8A) during the
period. On the other hand, qRT-PCR analysis also revealed an 80% drop in Fst288 mRNA (Fig. 8B) from PN17 to PN29. Thus PACAP mRNA is decreased in
parallel with pituitary Fst-288 expression, and is reciprocal to the rise in FSH
levels.
3.3. Effects of PACAP38 and PACAP antagonist 6-38 on gonadotropins in
immature male rats
Follistatin was known to inhibit FSH synthesis by binding activin and
limiting activin signaling to gonadotrophs (Katayama et al., 2000). Furthermore,
follistatin mRNA expression followed the same expression pattern as PACAP
from PN17-PN29. To further demonstrate the role of PACAP in the synthesis and
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secretion of gonadotropins in immature male rats, we utilized micro-pumps filled
with 2 g/ml PACAP 6-38 or PACAP38 to implant intraperitoneal in PN16 male
rats. Analysis of gonadotropins levels of experimental animals was processed at
3, 5 and 7 days after surgeries.
3.3.1. Effect of 3 days i.p. administration of PACAP 6-38 on gonadotropins in
immature male rats
We implanted intraperitoneal osmotic micro-pumps containing PACAP
antagonist PACAP 6-38 (2 g/ml) into PN16 male rats. After three days, both
serum gonadotropins (Fig. 9) and pituitary gonadotropins mRNA (data not show)
from surgical animals were analyzed and compared with vehicle and non-surgical
control rats. Neither LH nor FSH was affected by 3 days administration of
PACAP 6-38.
3.3.2. Effect of 5 and 7 days i.p. administration of PACAP 6-38 and PACAP38 on
gonadotropins in immature male rats
However, 5 and 7 days treatments in immature male rats cause significant
differences. Rats treated with 6-38 for 5 and 7 days had significantly higher levels
of both serum FSH and FSH mRNA than vehicle and nonsurgical control rats
(Fig. 10 and 11). On the other hand, PACAP38 treatment for 5 and 7 days
reduced levels of serum FSH and FSH mRNA compared to vehicles and
controls (not statistic significant). Based on these results, PACAP expression in
pituitaries of immature male rats contributes to suppression of FSH, and that an
endogenous decline in PACAP around PN17 allows for FSH expression to
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increase. Neither serum LH nor LH mRNA was affected by PACAP 6-38 or
PACAP38 (Fig.10C and D).
3.3.3. Effect PACAP 6-38 on Fst-288 and PACAP mRNA in immature male rats
The pituitary samples collected from PACAP 6-38 treated immature male
rats were analyzed for Fst-288 mRNA levels. PACAP 6-38 treated rats have
much lower (40-60%) follistatin levels than vehicles and nonsurgical controls. At
the same time, PACAP38 treatment increased Fst-288 level by about 50% (Fig.
12A). The data suggest that effect of PACAP on gonadotropins works through
follistatin-activin signaling pathway. PACAP mRNA in pituitary samples are also
affected by PACAP 6-38 and PACAP38, which PACAP 6-38 decreases the
PACAP mRNA level whereas PACAP 38 increases it (Fig. 12B). However, the
differences are statistically significant compared to vehicle animals but not
control animals, which may be induced by surgery procedure.
3.4. Effect of PACAP38 on follistatin promoter in L T2 cells
The in vivo experiments suggested that PACAP might induce follistatin
expression in immature male rats. To examine how PACAP could affect follistatin
expression, we investigated the activities of follistatin promoter utilizing a
luciferase-reporter construct under PACAP38 treatments. We chose L T2 cells
because they have similar low level of PACAP with our in vivo experimental
animals.
3.4.1. PACAP stimulates follistatin promoter in L T2 cells
Increasing doses of PACAP38 treatment proved that follistatin promoter
activity was stimulated more than 2-fold than medium alone at 10nM
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concentration (Fig. 13A). After PAC1-R variants, Short and Hop1 form, were
overexpressed in L T2 cells, the activity of follistatin promoter stimulated by
PACAP climbed to 2-fold higher than wild type in both short and hop1
overexpressed cells (Fig. 13B).
3.4.2 PACAP stimulates follistatin promoter through PKA and MAPK pathway
By sequence homology and previous research, we identified some
putative transcription factor binding sites on the follistatin promoter. Among these
sites, AP1 and CRE binding sites were important in MAPK and PKA pathway.
AP1, CRE and double mutant constructs were transfected into cells with or
without PAC1-R expression vectors. AP1 mutation didn’t significantly reduce the
activity stimulated by PACAP compared to wild type vector (Fig. 14A). PAC1-R
overexpression still induced PACAP stimulated activity. On the other hand,
PACAP stimulated activity decreased after CRE mutation, and overexpression of
PAC1-R got the similar pattern with native receptor types (Fig. 14B). Significant
decrease in PACAP stimulated activity happened after we mutated both AP1 and
CRE sites even when we overexpressed PAC1-R (Fig. 14C). All these data
suggest that PAC1-R-PKA pathway through CREB was the most important for
effect of PACAP on follistatin whereas MAPK pathway may also be involved in.
3.5. Microarray analysis revealed function of PACAP in gonadotrophs
We created a transgenic mouse model, in which we use GSU subunit
promoter to drive PACAP expression to maintain lifelong high pituitary PACAP
levels. To evaluate genes that could be either up- or down-regulated by pituitary
overexpression of PACAP, we performed gene chip microarray analysis
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comparing pituitary gene expression in wild type and GSU-PACAP mice.
Pituitaries were collected from postnatal day 35 mice, an age when the difference
in FSH and follistatin mRNA levels was maximal. Of the 45, 102 probe sets
present on the gene chip, 516 were at least ±1.5 fold different (357+, 159-) in the
GSU-PACAP mice (p<0.05). Adjusting to a more stringent criterion of at least ±
2-fold difference and consolidation of multiple probe sets for individual genes,
108 genes (73+, 35-) were significantly (p<0.05) altered by chronic pituitary
PACAP overexpression (Table 2). Among these genes, we found similar results
with our previous experiments. Follistatin was strongly stimulated by PACAP with
a 4-fold change. On the contrary, FSH was suppressed with a 3-fold decrease
(Table 2, bold letter). We did find some novel genes, which were regulated by
PACAP change. Two new genes that were affected the most by pituitary PACAP
over-expression were gastrin releasing peptide (GRP, +14.97-fold) and
“phosphate regulating gene with homologies to endopeptidases on the X
chromosome” (PHEX, -12.2 fold).
To gain biological insight into the changes in gene expression in the
pituitaries of GSU-PACAP mice, we utilized Pathway Analysis software from
Ingenuity Systems, Inc. (Table 3). These analyses revealed significant changes
in the expression of genes involved in established biological networks including
reproductive system disease, cancer, lipid metabolism, development and cellular
growth and proliferation. The top biological functions of the genes with altered
expression included neurological, endocrine, reproductive, genetic, and skeletal
disorders; cellular functions including lipid metabolism, morphology, and
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development; and physiological system functions including organ morphology
and development of the nervous and reproductive systems. Not surprisingly, the
top canonical pathway altered to the greatest extent was the GnRH signaling
pathway. Through the analysis, we also listed genes which were known to be
involved in pituitary function (Table 3). Furthermore, all the changes of selected
genes were confirmed by real-time PCR.
4. Discussion and Future Investigations
Previous studies demonstrated that PACAP and PAC1-Rs were present in
gonadotrophs during development. Subsequence investigations revealed some
functions of PACAP on gonadotrophs, like stimulating gonadotrophins secretion,
increasing subunit gene expression and lengthening LH mRNA transcripts
(Rawlings et al., 1994; Tsujii et al., 1994; Tsujii and Winters, 1995b). However,
most of these data were from in vitro studies, including pituitary cell culture and
L T2 and T3 cell lines. Very little information has come from in vivo
experiments. Previous studies documented that PACAP could suppress FSH
mRNA levels in pituitary cell cultures from adult rats (Winters et al., 1997).
Furthermore, PACAP was demonstrated to increase follistatin expression in rat
pituitary cell cultures and clonal FS cell line (Winters et al., 1997). As follistatin is
an activin-binding protein, high levels of follistatin within the pituitary would block
activin stimulation of FSH transcription in gonadotrophs (Katayama et al., 2000).
Therefore, PACAP may indirectly regulate FSH through follistatin then activin in
gonadotrophs.
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Our previous data revealed the decline of PACAP and follistatin mRNA
levels happened around birth in male rats (Moore et al., 2009a). At the same
time, follistatin mRNA levels begin to rise. In this dissertation, we could find
another period from PN17 to PN29, during which PACAP and follistatin were
decreasing whereas FSH was increasing (Fig. 7 and 8). Together, we noticed
that PACAP and follistatin mRNA expression were parallel and reciprocal with
FSH during the male rat sexual development. This evidence supports the
hypothesis that PACAP in vivo should have similar function on FSH as
observed in cell cultures. From PN16, we treated male rats with 0.5%BSA,
PACAP 6-38 or PACAP38 then collected serum and pituitary samples at PN19,
PN21 and PN23. After 3 day treatment, neither PACAP 6-38 nor PACAP38
showed the significant effect on FSH and LH levels in serum or pituitary (Fig. 9).
On the other hand, FSH serum levels in PN21 and PN29 after PACAP 6-38
treatment were significantly higher than controls and vehicles. PACAP38
treatment did show some decreasing trends but no statistically significant
differences were detected (Fig. 10 and 11). LH levels were not influenced by
either treatment.
Two alternatively spliced mRNAs are produced from follistatin gene, with
Fst-288 having greater activin-neutralizing activity (Hashimoto et al., 1997;
Sugino et al., 1997), and our experiments revealed that PACAP 6-38 treatment
decreased Fst-288 mRNA level in pituitary (Fig. 12A). These data provide the
first in vivo evidence in rats demonstrating a suppressive effect of PACAP on
FSH through regulating follistatin. In addition, we observed that PACAP regulates
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mRNA expression of itself, which is increased by PACAP38 treatment and
decreased by PACAP 6-38 (Fig. 12B).
Chapter two showed that the Short and Hop forms PAC1-R dominated in
developing rat pituitary and gonadotrph cell lines. In the present experiments,
overexpression the Short or Hop1 form in L T2 cells strongly increased PACAP
induced follistatin promoter activity (Fig. 13). Furthermore, AP1 and CRE site
mutations totally eliminated follistatin promoter activity induced by PACAP in wild
type L T2 cells. Single mutation of the CRE site showed significant reduction of
follistatin promoter activity in wild type L T2 cells but not in PAC1-R
overexpression cells whereas AP1 mutation result no significant decrease in wild
type cells and no effect in overexpression cells. All these data provide support
that PACAP regulates follistatin mRNA mainly through PKA pathway with both
Short and Hop1 forms involved. This result was not a surprise considering that
the main function of PACAP is to stimulate production of cAMP, which a key
factor inducing the PKA pathway.
Our lab also built a transgenic mouse line with high level pituitary PACAP
in both prenatal and postnatal period. Lifelong pituitary PACAP over-expression
in male mice was associated with decreased gonadotropin subunit mRNA levels,
lower circulating FSH and testosterone levels, which gave us additional in vivo
evidence about PACAP suppressing FSH. Gene chip analysis of PN35 male
wild-type mice and TG-mice confirmed a significant decline in FSH and an
increase in follistatin. PACAP overexpression in pituitary also modified the
expression of some novel genes not previously shown to be PACAP dependent.
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Some of these genes are known to affect pituitary function (Table 3). EGR1 (3.99 fold) was reported to activate LH and other gene promoters in
gonadotrophs. Gamma-aminobutyric acid (GABA) may either stimulate or inhibit
gonadotropin secretion depending on the physiological state of the
gonadotrophs. In PN35 PACAP overexpressing mice, we saw that GABA A
receptor, beta 2 isoform was significantly decreased (-2.56 fold). Neurod1 (+2.51
fold) has been shown to increase GnRH-R expression in immortalized mouse
gonadotroph cells. The gene with the highest fold change (+14.97) was Grp. In
rats, intravenous injection of GRP increases circulating LH levels and decreases
TSH concentrations. GRP also stimulates ACTH release from rat pituitary cells in
vitro and GRP peptide levels within the pituitary increase following repeated
stress in rats. GRP receptor is also found in the rat pituitary. Therefore, GRP
may play a role in pituitary gonadotroph function, and may be regulated by
PACAP. Other genes in the list have been demonstrated to be involved in
pituitary development, like Fgfr2 (+2.40 fold) and Tgfbi (+4.51 fold).
In summary, these data suggest that like the perinatal period, PACAP
plays a role in the suppression of FSH during the infantile period of development.
A significant decline in pituitary PACAP expression prior to puberty causes a
decline in follistatin expression allowing for stimulation of FSH expression by
locally derived activin. Advancing the decline in pituitary PACAP expression by
endogenous treatments of day 16 rats with a PACAP antagonist causes a timeadvanced and significant decline in pituitary follistatin and a reciprocal rise in
FSH expression.
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Future investigations are planned to evaluate the effect of pituitary PACAP
on the developing testis. In addition to PACAP overexpressing mice, we plan to
use conditional knockout mice, which could delete PACAP in specific tissue and
time point. Knockout of PACAP in pituitary after birth and around PN16 would
reveal more details about effect of PACAP in the postnatal pituitary
gonadotrophs.
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Figure 7. LH and FSH levels during male sexual development.
Serum LH and FSH (A) concentration in infant male rats were determined by
ELISA. The pituitary LH and FSH mRNA (B) levels of these animals were
expressed as levels relative to PN17 values. Each value represents the mean
±SEM of 6 rats per groups. * Significantly (P<0.05) different compared to PN17
levels.
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Figure 8. PACAP and Fst-288 mRNA levels during male rat sexual development.
PACAP mRNA (A) and Fst-288 (B) mRNA levels were determined by real-time
PCR after reverse-transcription and were expressed as levels relative to PN17
values. Each value represents the mean ±SEM of 6 rats per group. * Significantly
(P<0.05) different compared to PN17 levels.
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Figure 9. Serum FSH and LH levels after 3 days treatment of PACAP 6-38.
Micro-Osmotic pumps with vehicle (0.5% BSA) or 2 g/ml PACAP 6-38 antagonist
were surgically implanted (i.p.) in PN16 male rats, and 3 days later, serum
collected for determination of serum FSH (A) and LH (B) levels by ELISA. Each
value represents the mean ±SEM of 5 rats per group. * Significantly (P<0.05)
different with controls and vehicles.
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Figure 10. FSH and LH levels after 5 days PACAP 6-38 and 1-38 treatment.
Micro-Osmotic pumps with vehicle (0.5% BSA) or 2 g/ml PACAP 6-38 antagonist
or 2 g/ml PACAP 1-38 were surgically implanted (i.p.) in PN16 male rats, and 5
days later, RNA from Pituitary glands were isolated for determination of FSH (A)
and LH (C) mRNA levels, while blood was collected for determination of serum
FSH (B) and LH (D) levels by ELISA. mRNA data were normalized to controls
and each ELISA value represents the mean ±SEM of 5 rats per group. *
Significantly (P<0.05) different with control and vehicles.
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Figure 11. FSH levels after 7 days PACAP 6-38 and 1-38 treatment.
Micro-Osmotic pumps with vehicle (0.5% BSA) or 2 g/ml PACAP 6-38 antagonist
or 2 g/ml PACAP 1-38 were surgically implanted (i.p.) in PN16 male rats, and 7
days later, RNA from Pituitary glands were isolated for determination of FSH (A)
mRNA levels, while blood was collected for determination of serum FSH (B)
levels by ELISA. mRNA data were normalized to controls and each ELISA value
represents the mean ±SEM of 5 rats per group. * Significantly (P<0.05) different
with controls and vehicles.
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Figure 12. Fst-288 and PACAP mRNA level after PACAP 6-38 and 1-38
treatment. Micro-Osmotic pumps with vehicle (0.5% BSA) or 2 g/ml PACAP 638 antagonist or 2 g/ml PACAP 1-38 were surgically implanted (i.p.) in PN16
male rats, and 5 days later, RNA from Pituitary glands were isolated for
determination of Fst-288 (A) and PACAP (B) mRNA levels, mRNA data were
normalized to controls. * Significantly (P<0.05) different with controls and
vehicles.

Significantly (P<0.05) different with vehicles only.
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Figure 13. Effect of PACAP on follistatin promoter in L T2 cells.
L T2 cells were transfected with the mouse the Fst-luc promoter reporter
construct only (A) and with PAC1-R overexpression (Short and Hop1) (B), then
treated for six hours with increasing doses (A) or 10nM (B) of PACAP38. Data
are expressed as fold difference normalized to treatment with media alone. *
Significantly different than medium alone (p<0.05) by ANOVA. Results were from
three experiments with triplicate wells.
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Figure 14. Effect of PACAP on mutant follistatin promoters in L T2 cells.
L T2 cells were transfected with three types mutant Fst-luc alone, AP-1 (A) CRE
(B) and Double mutation (C), or together with PAC1-R-Short or Hop1 expression
vectors, then treated for six hours with medium alone or 10nM PACAP38. Data
are expressed as fold difference normalized to FBS-free media treatment of
transfected cells. * Significantly different than media alone (p<0.05) by ANOVA.
Significantly different than wild type by Tukey’s test. Results were from three
experiments with triplicate wells.
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Table 2. List of genes mostly regulated by PACAP overexpression.
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Table 3. IPA software analysis results
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CHAPTER FOUR

REGULATORY FACTORS OF PITUITARY PACAP EXPRESSION

1. Introduction
The synthesis and secretion of LH does not always parallel FSH as we
described in chapter three. The first physiological instance of differential
gonadotropin regulation in males appears during fetal development with the
predominance of LH over FSH (Chiappa and Fink, 1977; Chowdhury and
Steinberger, 1976; Ketelslegers et al., 1978; Moore et al., 2003). The reason for
this divergence is not known. Pituitary adenylate cyclase activating polypeptide
(PACAP) has been demonstrated to differentially regulate gonadotropin subunit
gene expression. PACAP stimulates -subunit transcription, lengthens LH
mRNA and presumably prolongs its half-life in rat pituitary cell cultures. However,
PACAP inhibits the synthesis of FSH by stimulating follistatin transcription in
gonadotrophs and folliculostellate cells (Carroll et al., 1989; Fujii et al., 2002;
Tsujii and Winters, 1995b; Winters et al., 1997). We reported previously that
PACAP and follistatin expression levels are high in the embryonic male pituitary,
and decline significantly and in parallel at birth at which time FSH mRNA levels
increase dramatically (Moore et al., 2009a). From these results, we hypothesize
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that continuous exposure of the embryonic anterior pituitary to PACAP facilitates
the early appearance of - and LH -subunits but delays ontogeny of FSH by
stimulating follistatin production and this hypothesis has been supported with our
in vivo data from the male rats and the transgenic mice in chapter three.
However, little is known about the mechanisms that regulate PACAP gene
expression in the pituitary. Treatment of rats with PACAP-38 increases pituitary
PACAP mRNA levels (Radleff-Schlimme et al., 1998). The PACAP promoter
contains sequence homologous to the CRE, and is activated by forskolin and by
PACAP itself in neuroblastoma cells and in PC12 cells (Kozawa et al., 1995;
Suzuki et al., 1994).
In the present study, we analyzed additional factors that could potentially
regulate PACAP expression, both through stimulation and suppression. We first
examined whether gonadal hormones have feedback on PACAP expression in
gonadotrophs. In addition, activation of Dopamine-2 Receptor (Drd2) was tested
as a potential down-regulation factor. The dramatic decline in pituitary PACAP
expression that occurs around the time of birth provides an excellent model to
examine developmental PACAP gene regulation in the pituitary. We propose that
developmental changes in both pituitary-derived and endocrine factors regulate
pituitary expression of PACAP, and the present studies were designed to begin
to understand the factors that regulate pituitary PACAP expression. We utilized
mouse PACAP promoter-reporter constructs (1.2 kb) transfected into T3 and
L T2 gonadotroph cells, as models of immature and mature gonadotrophs,
respectively. We measured basal and stimulated promoter activity in the two cell
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lines in the absence or presence of PACAP and demonstrate the involvement of
the PKA, PKC and MEKI signaling pathways in the activation of the PACAP
promoter. Furthermore, we identified potential promoter regions, important for the
regulation of PACAP gene transcription.
2.

Materials and Methods

2.1. Cell Culture
T3 and L T2 immortalized mouse pituitary gonadotroph cells were kindly
provided by Dr. Pamela Mellon (University of California, San Diego, CA). T3
cells were grown in Eagle’s Minimal Essential Medium (MEM) containing glucose
(4.5g/L), NaHCO3 (2.2g/L) and HEPES (5.96g/L), with penicillin, streptomycin,
and fluconazole, and supplemented with 10% fetal bovine serum (FBS). L T2
cells were grown in Dulbecco’s MEM (DMEM) containing HEPES (22.5mM),
NaHCO3 (40mM), 10% charcoal-stripped FBS, penicillin, streptomycin, and
fluconazole. Primary cell culture is the same as described in Chapter one.
2.2. Mouse PACpro-luc reporter constructs
A PCR generated cDNA fragment, including the promoter (-1218 - + 36)
region of mouse PACAP, was cloned separately into the pSTBlue-1 vector by TA
cloning. The cDNA were sequenced and found to be identical to published
sequences. The cDNA was excised with restriction enzymes and cloned into the
pGL3-Basic vector (Promega Corp., WI). Truncated promoter sequences were
produced utilizing the restriction enzyme Kpn I and one of four other enzymes (1018 by Spe I, -700 by Bst I, -541 by Nde I, -200 by AaT II) followed by re-
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ligation. CRE site mutation (-200) was constructed utilizing the restriction
enzymes Aat II, which broken the CRE site sequence.
2.3. Expression vectors
A dominant-negative inhibitor protein expression vector of CREB, termed
A-CREB, was obtained from Dr. Vinson (Department of Neuroscience, The
Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA).
A rat PAC1-R-Short expression vector was obtained from Dr. Laurent
Journot (National Center of Scientific Research, Montpellier, France). A human
PAC1-R-Hop1 expression vector was obtained from Dr. Eve Lutz (Royal College,
Glasgow, UK)
2.4. Cell Transfections
For transfections, T3 and L T2 cells were plated in 6-well plates at 1–
2×106 cells/well and used within 1–2 days at 50–80% confluency. Approximately
3h prior to transfection, the media were replaced with fresh media (MEM+10%
dextran-coated-charcoal-stripped FBS). Cells were transfected with Fugene-6 or
GeneJammer Transfection Reagent (Stratagene, CA) according to the
manufacturers’ protocols. For each plasmid, phRL-TK vector (Promega, WI) was
co-transfected into the cells (0.2mM) for use of Renilla luciferase expression to
monitor transfection efficiency. After 24 hours, cells were washed and incubated
with fresh media. After 48 hours, cells were treated with test substances for 6-8
hours; cells were then lysed and assayed for luciferase activity.
2.5. RNA extraction and reverse transcription
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Total RNA was prepared from cultured T3 and L T2 cells using QIAGEN
RNAeasy Kit following the instruction of manufacturer. 1 g total RNA from every
sample was reverse transcribed using Superscript III reverse transcriptase
(Invitrogen, CA) primed with oligo (dT) following the instructions from Invitrogen.
2.6. Cell Count
0.5 ml of primary cell suspension was placed in a 1.5ml tube, then 0.1ml
of 0.4% Trypin Blue (by GIBCO) was added with cells. Cells were staining for 5
minutes at room temperature. Metallized Hemacytometer (by Hausser) was filled
with stained cell suspension (about 100 l). Numbers were counted under the 20
Microscope then calculated using the following formula:
The number of cells per milliliter = Number of cells counted per square
millimeter
2.7. 2 -

C
T

dilution

10,000

Method for analyzing Real-time PCR results

Same procedure was used as described in Chapter three.
2.8. Microarray Analysis
Samples from wild type and PAC1-R-Hop1 overexpressed L T2 cells
treated with PACAP or medium alone are analyzed following the procedure
stated in Chapter three.
2.9. Statistical Analysis
All the luciferase assays and real-time PCR data were performed with at
least double samples and repeated at least three times. Values were expressed
as mean ± SEM. Statistical analysis was performed using ANOVA ant post
Tukey’s test if necessary. P<0.05 was considered statistically significant.
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3.

Results

3.1. Effect of Gonadal Hormones on PACAP expression
PACAP regulates gonadotropins synthesis and secretion and influence
gonadal hormones through modulating gonadal responses to gonadotropins. To
examine whether there are feedback mechanisms from gonadal hormones, we
treated T3 cells with increasing dose of hormones and analyzed PACAP mRNA
expression (data not show) and promoter activity (Fig. 15). No changes in
PACAP promoter activity were observed following various concentrations of
testosterone, estradiol, or progesterone exposure. These data suggest that
gonadal hormones within the circulatory system do not influence PACAP
expression in gonadotrophs.
3.2. Self-stimulation of PACAP
3.2.1. Effects of PACAP on mouse PACAP promoter activity in gonadotroph cell
lines
The in vivo results of the effects of PACAP and PACAP antagonist on
pituitary PACAP expression suggest that PACAP can self-regulate its own
expression. To examine how PACAP affects activation of the PACAP promoter in
gonadotrophs, we utilized a luciferase-reporter construct containing the mouse
PACAP promoter (-1218 - +36). Figure 16 shows that the PACAP promoter is
activated by PACAP in both T3 and L T2 cells but is more sensitive to
stimulation by PACAP in L T2 cells than in T3 cells (Fig. 16A and B).
3.2.2. Effects of PACAP on mouse PACAP promoter activity with PAC1-R
receptors overexpressed in gonadotroph cell lines
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The PAC1-R specific receptor has several splice subtypes (Spengler et al.,
1993). Figure 17A confirms that the level of expression of Hop1 exceeds PAC1-R
short in T3 cells (Rawlings et al., 1995), while both subtypes are expressed at
similar low levels in L T2 cells. We overexpressed the PAC1-R-Short or Hop1 in
T3 and L T2 cells (Fig. 17A). When these cell lines were also transfected with
the PACpro-luc reporter construct, 10nM PACAP significantly increased PACAP
stimulated promoter activation more strongly in PAC1-R-Short and PAC1-RHop1 cells than in wild type (WT) T3 or L T2 cells. Compared to WT L T2 cells,
PAC1-R Short overexpression induced a 3-fold increase in PACAP promoter
activity, while PAC1-R-Hop1 overexpression resulted in a 4-fold increase in
PACAP activation of the PACAP promoter compared to stimulation in WT cells
(Fig. 17C). Based on the level of expression following transfection (Fig, 17A), the
Hop1 form appears to be more effective than the short form in increasing PACAP
stimulated PACAP promoter activity in L T2 cells. In T3 cells, on the other hand,
only PAC1-R-Short overexpression significantly increased PACAP stimulation of
the PACAP promoter. Thus the PAC1-R-Hop1 is more effective in transducing
the PACAP signal in mature L T2 than in immature T3 cells (Fig. 17B).
3.2.3. Evaluation of second messenger cascades involved in stimulation of the
PACAP promoter
PACAP has been demonstrated to increase cAMP production, PKC
activity and Ca2+ mobilization (Miyata et al., 1989; Niewiadomski et al., 2002;
Rawlings et al., 1993; Taupenot et al., 1999). However, little is known about the
signaling pathways by which PACAP stimulates the PACAP promoter. To
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determine the important pathways that regulate PACAP promoter activity, we
used the pharmacological inhibitors BIM (PKC inhibitor), H-89 (PKA inhibitor) and
PD98059 (MAPK inhibitor) in cultures of T3 and L T2 cells transfected with the
mPACpro-luc. Basal promoter activity in T3 cells was decreased when the PKA
(50%) or MAPK (30%) pathways (Fig. 18A) were inhibited but not when PKC
signaling was blocked with BIM at doses previously shown to inhibit forskolinstimulated follistatin promoter activity (Winters et al., 2007). In contrast, basal
promoter activity was reduced by H89 but was unaffected by PKC or MAPK
inhibitors in L T2 cells (Fig. 18B). In T3 cells stimulated with PACAP, H-89 and
PD98059 markedly decreased PACAP promoter activity while BIM was less
effective (Fig. 18C). These results demonstrate that the PKC, PKA and MAPK
pathways are all involved in PACAP induced promoter activity and suggest that
the PKA and MAPK pathways are more critical mediators of PACAP promoter
activity in T3 cells.
3.2.4. Regional analysis of basal and stimulated mouse PACAP promoter activity
in T3 and L T2 cells
By sequence homology and previous research, we identified a series of
putative binding sites for transcription factors on the PACAP promoter that share
at least 80% homology to their consensus sequences and are present in pituitary
(Fig. 19) (Ohkubo et al., 1992; White et al., 2000). Based on these findings, we
constructed five mouse PACAP promoter reporter constructs, each with a
sequential truncation of approximately 200 bp, and treated T3 and L T2 cells
for 6 hours with 10nM PACAP or control media.
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Fig. 19A and B showed the basal activity changes after sequential cutting.
We found two regions that may mediate an inhibitory signal to the PACAP
promoter. One element is located between position -700 and -541 and is
effective both in T3 and L T2 cells. The second region, between -1218 and 1018, appears to possess inhibitory binding sites but only in T3 cells. In figure
19C and D, in which cells were treated with PACAP, a second element (-1218 to
-1018) was essential for maximum PACAP induced activity in T3 but not in
L T2 cells. The promoter region from -541 to -200 contains elements that
mediate the effects of PACAP because deletion of this region resulted in a
pronounced loss of promoter activation in both cell lines (Fig. 19C and D).
However, the element (-700 to -541) does not influence PACAP induced
promoter activity.
3.2.5. PACAP promoter activity required CRE site
PKA and MAPK signaling mediate PACAP expression in gonadotrophs,
and serial deletions of the PACAP promoter identified the -541 to -200 region to
be critical for promoter activity. This region of the mouse PACAP promoter
contains regions with similarity to the consensus CRE element, a well-described
mediator of PKA signaling. Furthermore, we have evidence that PACAP induces
CRE activities utilizing a luciferase reporter construct with a CRE element in both
cell lines. Therefore, T3 and L T2 cells were transfected with the mPACpro-luc
construct and with increasing concentrations of an expression plasmid encoding
a dominant negative inhibitor of CREB (A-CREB) and a filler plasmid. A-CREB
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decreased both basal (Fig. 20A) and PACAP-induced (Fig. 20C) promoter
activity dose-dependently to a similar extent in T3 and L T2 cells.
We also designed a CRE site mutant (around -200) mPACpro-luc
construct and transfected it into both T3 and L T2 cells. In T3 cells, CRE site
mutation almost totally blocked PACAP induced promoter activity compared to
WT construct, whereas in L T2 cells PACAP induced a little activity with mutant
construct but not statistic significant (Fig. 21A and B). Furthermore,
overexpression of the PAC1-R-Short or Hop1 forms in L T2 cells could not totally
abrogate this inhibition but caused a significant increase compared to medium
alone (Fig. 21C).
3.2.6. Gene-array analysis L T2 cells overexpressed PAC1-R and treated with
10nm PACAP
To evaluate novel genes that could be either up- or down-regulated by
PACAP signaling, we performed gene chip microarray analysis comparing
untreated or 10 nM PACAP treated L T2 cells and PACAP treated L T2 cells
with Hop1 overexpression. As depicted in Table 4, six hour PACAP38 treatment
of L T2 cells transfected with control vector resulted in significant (p<0.01,
change > 20%) alterations in 223 genes (106 increased, 117 decreased).
PACAP38 treatment of PAC1-R-Hop1 transfected L T2 cells resulted in
significant alterations of 393 genes (171 increased, 222 decreased), of which,
113 (44 increased, 69 decreased) were common to PACAP treated control cells.
Ingenuity Systems Pathway Analysis revealed significant changes in gene
expression of putative molecules related to specific canonical pathways (Table 4).
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PACAP treatment of control and PAC1-R-Hop1 transfected L T2 cells resulted in
significant changes in molecules in pathways known to regulate gonadotroph
function such as, increases in the PKA (PRKACB, CREM) and PI3K/AKT (cRAF,
Bcl-XL, p21cip1, eNOS) signaling pathways while decreasing molecules in the
ERK/MAPK (Myc, PIK3R1, TLN2) and BMP (BMPR2, Runx2) pathways.
Overexpression of the PAC1-R-Hop1 receptor leads to additional changes in
gonadotroph regulatory pathways including significant increases in molecules in
the JAK/STAT (Bcl-XL, p21cip1, RAF1, CDKN1A), TGF- (INH , RAF1, HNF)
and Interleukin (BAX1, RAF1, GNB3, CDH1, CXCL 10/11, I-TAC) signaling
pathways and significant decreases in molecules in the GnRH (EGR1, GnRHr),
insulin and IGF-1 (FOX01, SOCS2), EGF (NRAS, PIK3R1, MAP3K), Wnt/ catenin ( -catenin, ACVR1, ACVR2A, Frizzled family receptor), estrogen and
androgen (HSP90, SRY) signaling pathways. Many other molecules related to
signaling pathways not previously associated with gonadotroph functioning were
also significantly altered.
3.3. Dopamine-2 Receptor activation Decreases PACAP expression in rat
pituitary gland
Last section tells us that PACAP stimulated itself through PKA pathways
as one of the positive regulators in addition to GnRH (Grafer et al., 2009a). We
proposed one potential negative regulator (dopamine) that might interrupt
PACAP expression in gonadotrophs. The dopamine-2 receptor, Drd2, has been
demonstrated to be expressed in T3 and L T2 gonadotroph cell lines (Kanasaki
et al., 2002; Mutiara et al., 2006). Drd2 couples to G I to inhibit adenyl cyclase
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activity, and reduce cAMP levels (Missale et al., 1998) whereas PACAP
increases the level of cAMP in gonadotroph cells. Furthermore, Dopamine
production increases near birth in the rat hypothalamus, the main control center
of pituitary (Hooghe-Peters et al., 1988). It is possible that dopamine activates
gonadotroph Drd2 to suppress cAMP production, which can induce a decreased
PACAP expression.
To prove the possibility that Drd2 activity is involved in regulating pituitary
PACAP expression, pituitary cell cultures were prepared from E19 rats, and were
treated for 24 hours with the dopamine receptor agonists (Bromocriptine and
BIM53097) or with PACAP antagonist 6-38. Both PACAP 6-38 and dopamine
receptor agonists lowered PACAP expression (Fig. 22).
4.

Discussion and Future Investigations
The mammalian gonadotropins, Luteinizing hormone (LH) and Follicle-

stimulating hormone (FSH) play a critical role in the regulation of reproductive
development and function. In females, an acute rise in circulating LH triggers
ovulation and development of the corpus luteum while FSH stimulates the
maturation of follicles in the ovary. In males, LH stimulates Leydig cell production
of testosterone, and FSH stimulates primary spermatocytes to undergo the first
division of meiosis to form secondary spermatocytes (Dorrington and Armstrong,
1979; Leung and Armstrong, 1980; Louvet et al., 1975). Interestingly, LH and
FSH expression are not always parallel during important physiologic functions.
Compared to LH, FSH is more prominent in mature mammals whereas during
fetal life, a lower level of expression of FSH may prevent the early maturation of
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the reproductive system. Since PACAP was discovered as a hypothalamicreleasing factor, and is known to be expressed in the gonadotrophs of the
anterior pituitary, subsequent research has revealed its potential functions in
reproduction. PACAP contributes to the regulation of gonadotrope function
through several mechanisms: directly on gonadotropes, either alone or by an
interaction with GnRH signaling, indirectly, by modifying GnRH release or GnRH
receptor expression, and through paracrine/autocrine actions (Counis et al., 2007;
Culler and Paschall, 1991; McArdle et al., 1994; Ortmann and Diedrich, 1999;
Tsujii and Winters, 1995a). For example, there is evidence that PACAP
suppresses FSH expression before birth through stimulation of follistatin. Most
importantly, in Chapter three, we proved that PACAP suppresses FSH
expression during male rat sexual development through stimulation of follistatin.
Follistatin binds with Activin to prevent stimulation of FSH transcription (Fujii et
al., 2002; Moore et al., 2009b). Therefore, the PACAP expression pattern is
important for reproductive development, and it is important to evaluate the factors
involved in the regulation of PACAP expression. Compared to the number of
studies of PACAP functions, however, only a few papers have described
regulation of PACAP expression. PACAP has been shown to up-regulate its own
level of expression in several cell lines, and injection of PACAP (10 g bolus)
increased PACAP mRNA expression in the pituitary of adult rats (RadleffSchlimme A, 1998). GnRH was found to increase PACAP expression in L T2
cells through PKA and PKC pathways (Grafer et al., 2009b). Within the HPG axis,
gonadal hormones have some feedback to the hypothalamus GnRH expression.
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However, only estrogens and progesterone are found to stimulate PACAP in the
rat hypothalamus (Apostolakis et al., 2004; Ha et al., 2000).
Our experiments revealed that gonad hormones could not stimulate or
suppress PACAP promoter activity in gonadotroph cell lines (Fig. 15). Therefore,
there is no direct feedback connection between gonadal hormones and
gonadotroph PACAP expression. But we cannot ignore the possibility that
gonadal hormones regulate PACAP indirectly through other factors, like GnRH.
PACAP increase its own level of expression in several cell lines and in
the rat pituitary. The results from Chapter three tell us that PACAP treatment
increases its pituitary PACAP mRNA levels in immature male rats whereas
antagonist decreases the level. PACAP antagonist decreases PACAP mRNA
expression in E19 primary pituitary cell cultures as well. To gain more information
about PACAP self-stimulatory function, we designed experiments to study the
mouse PACAP promoter. The -1280 to +36 region of the mouse PACAP
promoter was cloned into a luciferase-reporter plasmid. The promoter was active
in both gonadotroph cell lines, and was stimulated 4-fold by PACAP even though
the level of expression of PAC1-R is much lower in L T2 cells. Furthermore,
dose response curves revealed that L T2 cells are more sensitive to PACAP
treatment than T3 cells. These differences may be due to the much higher level
of PACAP expression in T3 cells. Overexpression of the PAC1-R-Short or Hop1
forms substantially increased PACAP stimulated PACAP promoter activity in
L T2 cells with a much smaller increase in T3 cells. The Hop1 form was also
more effective than the Short form in L T2 cells even though the level of
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overexpression of the two receptors was similar. The various cassettes of PAC1R are couple to different second messengers, and while both isoforms stimulate
cAMP production Hop1 also stimulates PLD (McCulloch et al., 2000). The much
lower level of expression of PAC1-R in L T2 than T3 cells may also partly
explain this finding. In T3 cells, there already exists a high level of endogenous
PACAP expression, which may mask the effect of exogenous PACAP treatment.
PAC1-R is known to activate several signaling pathways including the
PKA, PKC and MAPK-pathways (Dickson and Finlayson, 2009; Holighaus et al.,
2011; May et al., 2010). BIM, H-89 and PD98059 were used to disrupt the PKC
PKA, and MAPK pathways, respectively, in un-stimulated or PACAP-stimulated
T3 and L T2 cells. The results imply that the PKA pathway plays a key role in
PACAP promoter activity both in T3 and L T2 cells. Blocking the MAPK
pathway also markedly inhibited basal and PACAP stimulated PACAP
expression in T3 cells providing the first evidence for MAPK regulation of
PACAP in gonadotrophs. On the other hand, MAPK signaling plays a lesser role
in PACAP expression in the more mature L T2 cell line.
In a regional analysis of the mouse PACAP promoter, we found three
potential regions, which could play a role in pituitary PACAP expression. The
region between -1280 and -1080 appears essential for maximal basal and
PACAP stimulated activity in T3 whereas -541 to -200 is important for basal and
stimulated activity in both cell lines. In addition, we found that the putative CREB,
Jun and AP1 sites, which are important in PKA and MAPK pathways, are
essential for maximal PACAP expression. The region from -700 to -541 is more
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critical for promoter activity in L T2 cells. It may mediate an inhibiting signal for
PACAP regulation in both cell lines. In this region, there is an important transcript
factor binding site for pituitary function, SMAD3. SMAD3 has been demonstrated
to be essential for Activin and GnRH active FSH expression (Coss et al., 2007;
Coss et al., 2010). Through Chapter three, PACAP might inhibit FSH through
follistatin binding with activin. During pituitary development, it is possible that
some factors connected with SMAD3 pathway could suppress PACAP
expression after birth. Similar interactions could exist for other factors in this
region such as STAT, GATA3. The differences between L T2 and T3 cells may
be caused by different maturity levels and imply that signaling pathways are
changing during development.
Through the PACAP promoter regional analysis, -541 to -200 is critical for
promoter activities in both cell lines. Sequence analysis revealed a putative CRE
binding site located at around -210. Its binding protein CREB family is believed to
depend on PKA pathway (Meinkoth JL, 1993). Co-transfecting the luciferasereport construct with CREB dominant-negative construct to T3 and L T2 cells
showed CRE pathways were definitely involved in PACAP basal and stimulated
promoter activity. The same result was received when we used CRE-site mutant
mPACpro-luc construct. Furthermore, overexpression of PAC1-R receptors did
not have any influence on these results. So stimulation of PACAP promoter
needs participation of CRE- family. And the results proved that PKA signaling
induced transcript factor CRE-family binding to PACAP promoter may be the
most important regulation pathway for PACAP.
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Global analysis of alterations in gene expression in L T2 cells in response
to PACAP stimulation confirmed known changes in gene expression and
revealed changes in molecules previously not associated with PACAP signaling.
PACAP receptors are known to stimulate the PKA and PI3K pathways, and
molecules associated with these pathways were increased significantly in
response to 6h PACAP exposure. Surprisingly, Ingenuity Pathway Analysis
predicted a net decrease in ERK/MAPK signaling (Table 4) in response to
PACAP; however, MEK1 and MEK2 were both increased by PACAP perhaps
through an alternate intracellular signaling pathway. Confirmation of the
importance of MAPK signaling was demonstrated by a significant decrease in
PACAP promoter activity in the presence of a MEK1 inhibitor (Fig. 18). The
predicted decrease in BMP signaling was strongly influenced by the significant
decrease in BMP receptor type II expression. BMP has been demonstrated to
selectively increase synthesis and secretion of FSH while PACAP has the
opposite effect (Huang et al., 2001; Otsuka and Shimasaki, 2002; Takeda et al.,
2007; Takeda et al., 2003) so that the decreases in BMP receptor expression
and signaling may contribute to the selective down regulation of FSH in response
to PACAP. Of particular interest were the changes observed in gene expression
following overexpression of the Hop1 isoform of the PACR-1 receptor. Increased
PACAP signaling through the Hop1 receptor lead to increases in molecules
related to interleukin signaling including molecules in the JAK/STAT signaling
cascade. The interleukins have been shown to inhibit gonadotropin release, and
stimulation of various interleukin signaling pathways may have a role in the
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suppressive effect of PACAP on FSH production (Bilezikjian et al., 1998; Feng et
al., 1991; Karanth and McCann, 1991; Murata and Ying, 1991; Yamaguchi et al.,
1990). The predicted decrease in TGF signaling was strongly influenced by
observed decreased expression of the activin receptors I and IIa. TGF is a
potent stimulator of FSH secretion (Ying et al., 1986) and stimulates FSH
mRNA expression (Suszko and Woodruff, 2006). This observation suggests yet
another mechanism by which PACAP can inhibit the expression of FSH. The
gene array results also suggest that PACAP may have a role in mediating the
effects of EGF, IGF-1, insulin, Wnt/ -catenin and through each of these pathways
was predicted to be reduced following PACAP exposure of cells with PAC1-RHop1 overexpression (Gardner et al., 2010; Gutierrez et al., 2007; Mouihate et al.,
1996; Navratil et al., 2009; Weiss et al., 2003; Weiss et al., 2006; Xia et al., 2001).
Of particular interest were the effects of PACAP exposure on GnRH signaling.
Six hour PACAP exposure resulted in significant decreases in GnRH receptor
expression and signaling, and in Egr1 expression in L T2 cells with PAC1-RHop1 overexpression. A decrease in these molecules was also observed in
transgenic mice that overexpress PACAP in the pituitary (Moore et al., 2012).
Pituitary PACAP transgenic mice have lifelong suppression of gonadotropin
secretion due in part to increased follistatin and decreased Egr1 and GnRH
receptor expression. The global gene expression analysis reveals that PACAP
may interact with multiple extracellular and intracellular signaling pathways to
regulate gonadotroph function.
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Dopamine activates five types of G-protein coupled receptors, D1-D5, and
their variants. Drd2 is expressed at a high level in pituitary, and we found it in
T3 and L T2 cell lines. Furthermore, single cell analysis demonstrated that
Drd2 mRNA and PACAP mRNA co-localized in some cells. Two Drd2 agonists,
Bromocriptine and BIM53097, suppressed PACAP mRNA expression in E19 rat
pituitary cell cultures respectively (Fig. 22). All these data implied the
suppressive effect on PACAP might be through the activation of Drd2. In addition,
dopamine levels in the CNS rise dramatically during the perinatal period, while
PACAP mRNA begins to decrease (Hooghe-Peters et al., 1988). In future
experiments, we will utilize in vitro systems to examine the cAMP levels changes
after treatment of Drd2 agonists and validate that activation of Drd2 reduce its
levels. Furthermore, pharmacological inhibitors of different signaling pathways
will be utilized to reveal which pathways are involved in this suppression function.
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Figure 15. Effect of Gonadal hormones on PACAP promoter activity.
The mPACpro-luc construct was transfected into T3 cells, then treated cell with
increasing dose of gonadal hormones for 24 hours. Data are expressed as fold
difference normalized to medium alone. * Significantly different than media alone
(P<0.05) by ANOVA. Results were from three experiments with triplicate wells.
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Figure 16. PACAP induced promoter activity in T3 and L T2 cells.
T3 (A) and L T2 (B) cells were transfected with the mPACpro-luc construct and
treated for six hours with increasing concentrations (0-100nM) of PACAP. Data
are expressed as fold difference normalized to media alone. * Significantly
different than media alone (P<0.05) by ANOVA. Results were from three
experiments with triplicate wells.
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Figure 17. Effect of overexpression PAC1-Rs on PACAP stimulated activity of
promoter. PAC1-R mRNA isoform expression in wild type T3 and L T2 cells
and cells transfected with PACR-1 short or PACR-1 hop expression vector (A).
T3 cells (B) and L T2 (C) were transfected with the mPACpro-luc (2.5 g) and
PAC1-R express vector (50ng) and treated for six hours with 10nM PACAP. Data
are expressed as fold difference normalized to media alone. * Significantly
different than media alone (P<0.05) by ANOVA.

Significantly different than

Wild type cells with 10nM PACAP (P<0.05) by Tukey’s Test. Results were from
three experiments with triplicate wells.
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Figure 18. Pathway analysis on PACAP promoter activity.
T3 (A, C) and L T2 (B, D) cells were transfected with the mPACpro-luc
construct and treated for six hours with media alone (A,B) or 10nM PACAP (C,D)
with or without the indicated concentrations of the PKC inhibitor,
bisndolylmaleimide (BIM), the PKA inhibitor, H89, or the MEK1 inhibitor,
PD98059. Media alone groups used Renilla luciferase test. Data are expressed
as fold difference or stimulation normalized to media alone. * Significantly
different than media alone (p<0.05) by ANOVA. Results were from three
experiments with triplicate wells.
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Figure 19. Region analysis of PACAP promoter.
Top of the figure is schematic diagram depicting the regions of the mouse
PACAP promoter utilized in this investigation. T3 (A, C) and L T2 (B, D) cells
were transfected with DNA constructs containing various lengths of the mouse
PACAP promoter reporter construct (mPACpro-luc) and treated for six hours with
media alone (A, B) or media containing 10nM PACAP (C, D). Media alone
groups used Renilla luciferase test. Data are expressed as fold difference
normalized to media alone treatment of mPACpro-luc transfected cells. *
Significantly different than basal -1218 promoter activity. Results are from three
experiments with triplicate wells.
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Figure 20. Effect of CREB inhibitor on PACAP promoter activity.
T3 (A, C) and L T2 (B, D) cells were transfected with the mPACpro-luc
construct and with the indicated concentrations of expression plasmid coding for
the dominant negative inhibitor of CREB (A-CREB), and a filler plasmid (CMV500) to control for total transfected DNA amount. Transfected cells were treated
for six hours with media alone (A, B) or 10nM PACAP (C, D) and the cell lysates
were collected for luciferase activity determination. Data are expressed as fold
difference or stimulation normalized to media alone. * Significantly different than
media exposure alone (p<0.05) by ANOVA. Results were from three experiments
with triplicate wells.
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Figure 21. Effect of CRE-site mutation on PACAP promoter activity.
T3 (A) and L T2 (B, C) cells were transfected with the CRE-mutant mPACproluc (A, B) construct and with the PAC1-R expression plasmid (C). Transfected
cells were treated for six hours with media alone and 10nM PACAP and the cell
lysates were collected for luciferase activity determination. Data are expressed
as fold difference to media alone. * Significantly different than media exposure
alone (P<0.05) by Tukey’s test. Results were from three experiments with
triplicate wells.
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Table 4. PACAP induced signaling pathways in gonadotroph cells.
Canonical pathways with molecules significantly affected by alterations in gene
expression elicited by PACAP signaling.
transfected cells.
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Significantly greater in PAC1-R-Hop1
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Figure 22. Effect of PACAP 6-38, Drd2 agonists on PACAP expression in E19
pituitary cell cultures. Cells were cultured for 24 hours before treated with 100nM
PACAP 6-38, 1 M and 5 M Bromocriptine, or 0.1 M and 1 M BIM53097, or
control medium for 24 hours. PACAP mRNA level was tested by real-time PCR
and

T

method of normalization to control value. Values

are the mean ± SEM (n=3) experiments. * Significant different (P<0.05) than
control.
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CHAPTER FIVE

SUMMARY AND SIGNIFICANCE

It is already more than 20 years since PACAP was discovered in ovine
hypothalamus. Previous studies have demonstrated diverse functions of PACAP
in many different biological systems and animal models from the molecular level
to physiological characterization. This dissertation investigates the developing
rodent pituitary, with a focus on the role of PACAP in the regulation of
gonadotrophs in the anterior pituitary. PACAP as well as its receptors are
demonstrated to play a role in the function of pituitary gonadotrophs.
PACAP mRNA levels in the rat pituitary show a dramatic decline after birth,
and a low level of expression in adults. Single cell PCR of pituitary cells reveals
that PACAP is mostly present in gonadotroph cells from both E19 and PN1 rats.
Therefore, the perinatal decrease of PACAP expression in the pituitary is mainly
contributed by changes in gonadotroph cells. In addition, we observed significant
differences in PACAP mRNA levels between two gonadotroph cell lines, T3 and
L T2. We utilized T3 and L T2 gonadotroph cells, representing immature and
mature gonadotroph stages for in vitro experiments. We evaluated PAC1-R
mRNA expression levels from the E14 to PN10 rat pituitaries. Furthermore, we
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demonstrate that PAC1-R-Hop and PAC1-R-Short form are predominate during
rat pituitary development as well as in the T3 and L T2 cell lines, which
suggests that actions of PACAP in pituitary gondatrophs are mediated by the two
receptor subtypes.
During early sexual development of male rats, we implanted osmotic
micro-pumps containing PACAP38 or the PACAP antagonist, PACAP 6-38, into
the peritoneal cavities. After 5 or 7 days treatment, PACAP 6-38 causes an
increase of FSH levels in both serum and pituitary whereas PACAP 1-38
decrease the FSH levels. However, neither treatments change the LH levels. In
addition, Fst-288 mRNA levels in pituitary are suppressed by PACAP 6-38 and
stimulated by PACAP 1-38. In summary, the results provide the first in vivo
evidences of PACAP regulation of FSH, likely through its regulation of local
follistatin levels. Furthermore, we demonstrate that PACAP induces high
follistatin promoter activity through PKA pathways and mediated by PAC1-Rs in
the gonadotroph cells utilizing the follistatin promoter reporter vectors. The
results demonstrate the hypothesis that high level PACAP in fetus suppresses
FSH expression through follistatin-activin mechanism. Therefore, the increase of
FSH after birth is caused by the decreased PACAP.
Besides the studies on PACAP actions in pituitary gonadotroph, the
dissertation gives more information about regulation of PACAP expression.
PACAP expression in gonadotrophs is not regulated by feedback mechanism
from gonadal hormones. However, we observed a decrease of PACAP mRNA
after treatment of PACAP 6-38 both in vitro and in vivo, which suggests PACAP

107

may be stimulated by itself. Subsequent studies reveal that PACAP stimulates its
promoter in the T3 and L T2 cell lines through PKA and MAPK pathway, and
the existence of a proximal CRE binding site is required. In addition to positive
regulation, a potential inhibitory factor was discovered and evaluated in this
dissertation. Activation of Dopamine-2 receptor suppresses PACAP mRNA
expression in cultured E19 rat pituitary cells. Therefore, the stimulation of PACAP
on itself may contribute to the high level PACAP in the fetus while Drd2 activity
may mediate the decline of pituitary PACAP at birth.
The importance of differential regulation of gonadotropins by PACAP
during sexual development in humans is not yet known. However, as in rodents,
human preterm infants have less FSH than LH (Massa et al., 1992), and PACAP
increases follistatin mRNA levels in primate FS cell-enriched pituitary cultures
(Kawakami et al., 2002). Thus, PACAP might also differentially regulate
gonadotropins during human sexual development. Furthermore, many symptoms
of the reproductive diseases relate to abnormal levels of gonadotropins in the
human. For example, polycystic ovary syndrome (PCOS), which is characterized
by menstrual dysfunction and hyperandrogenism in the female, shows low to
normal FSH levels in the face of increased LH (Hall et al., 1998). The drugs
utilized for treatment usually will regulate both FSH and LH levels through
stimulating GnRH. Our investigations in this dissertation suggest that it is
possible to specifically regulate FSH levels through PACAP-follistatin-activin
mechanism. Therefore, PACAP and PAC1-R might be the targets of drug
designs for the gonadotroph disorders.
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In conclusion, PACAP is a novel regulatory factor for pituitary
gonadotrophs. PACAP is involved in the differential regulation of the
gonadotropins that occur during the perinatal and infantile periods in the male rat.
In the fetus, high level of PACAP, increases follistatin expression thereby
suppressing FSH through blocking the stimulatory function of activin. The high
levels of fetal pituitary PACAP could possibly be induced by self-stimulation
through high levels of pituitary or hypothalamic PACAP expression. After birth,
pituitary PACAP levels decrease significantly causing a decline of local follistatin
levels and allows for activin stimulation of FSH (Fig. 23). Our data suggests that
the perinatal decline in pituitary PACAP expression may be the result of a
significant increase in Drd2 activation through increased dopamine exposure or
responsiveness. Further research is needed to determine the importance of
PACAP in reproductive system development of the human.
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Figure 23. Schematic diagram of the dissertation summary.
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